



MATRIX METALLOPROTEINASE RESPONSIVE SILK- 
 
ELASTINLIKE PROTEIN POLYMERS FOR 
 
















A dissertation submitted to the faculty of 
The University of Utah 














Department of Pharmaceutics and Pharmaceutical Chemistry 
 
The University of Utah 
 
May 2015  
All rights reserved
INFORMATION TO ALL USERS
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted. Also, if material had to be removed, 
a note will indicate the deletion.
  
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States Code
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor,  MI 48106 - 1346
ProQuest 3728120
Published by ProQuest LLC (2015).  Copyright of the Dissertation is held by the Author.



















Copyright © Robert Andrew Price 2015 
 














The dissertation of Robert Andrew Price 
has been approved by the following supervisory committee members: 
 
Hamid Ghandehari , Chair 02/26/2015 
 
Date Approved 
Joseph Cappello , Member 02/26/2015 
 
Date Approved 
Jindrich Kopecek , Member 02/26/2015 
 
Date Approved 
Carol Lim , Member 02/26/2015 
 
Date Approved 




and by David Grainger , Chair/Dean of  
the Department/College/School of Pharmaceutics and Pharmaceutical Chemistry 
 

















Treatment methodologies employed in the management of head and neck cancer must 
be carefully chosen and matched to each patient. Currently, surgical resection with 
adjuvant chemotherapy and radiation are the standard of care; however, these often cause 
disfigurement and scarring in addition to the toxic effects of chemotherapeutics. There 
are benefits to a locally applied controlled release matrix that is capable of completely 
resorbing into the body, and responding to the invasiveness of each case by increasing 
delivery rate as a function of microenvironment.  Matrix metalloproteinase (MMP) 
responsive silk-elastinlike protein polymers (SELPs) show potential for development of 
such matrices. MMPs, a class of enzymes overexpressed in a variety of tumors including 
head and neck cancer, are an ideal target for the design of a tumor responsive controlled 
release depot. SELPs as a class of polymers have shown benefit in matrix mediated viral 
gene delivery to solid tumors; however, in this dissertation it is shown that despite 
superior safety, tumor size suppression, and survival prolongation in a murine cancer 
model do not readily resorb. Through recombinant DNA technology new SELP 
analogues based on SELP815K were designed and synthesized. MMP-responsive SELPs 
with insertion sites in the three structurally distinct regions termed SELP815K-RS1, 
SELP815K-RS2, and SELP815K-RS5 were tested for physiochemical similarity to their 





increase in minimum gel forming concentration, soluble fraction, and swelling ratio as a 
function of proximity to the main structural unit, the silk blocks. High shear force was 
used to condition the matrices and normalized properties more closely to SELP815K. The 
resultant materials were assayed for degradation in the presence of MMP-2, as well as in 
a murine model of head and neck cancer. All MMP-responsive polymers showed 
increased degradation with SELP815K-RS1 and SELP815K-RS2 degrading most 
effectively as evidenced by soluble fraction released from hydrogels. Similarly, upon in 
vivo application these two polymers exhibited the most favorable properties including 
increased degradation, tumor suppression, and survival elongation. These results lead the 
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Gene therapy has long been heralded as a potential cure to the root cause of many 
human diseases.(1-3) Delivering nucleic acids safely and effectively within the human 
body has, however, thus far presented an obstacle limiting the application of gene 
therapy.(4, 5) There are many mechanisms present within biological systems that have 
evolved to quickly remove foreign genetic material and carriers from circulation in order 
to protect the system from virulent threats.(6-8) In order to safely circumvent these innate 
defense systems, the field of nucleic acid delivery has expanded greatly to encompass 
both de novo engineered nucleic acid vectors and delivery strategies as well as re-
engineered viruses.(2) While engineering of novel delivery methods has produced viable 
methods of effectively transducing nucleic acids into cells, the targeting of only specific 
cell types has thus far remained elusive. Off target transduction of nucleic acid sequences 
represents one of the primary modes of toxicity seen upon in vivo application of these 
systems, particularly with respect to enabling cellular suicide as is the case in many 
schematics of cancer gene therapy.(9, 10)  Thus far these issues have primarily limited 
successful carrier application to the in vitro setting. As a consequence the development of 





therapy forward to successful treatment of diseases in vivo.(11) 
The approach of using re-engineered viruses represents the most efficient 
transduction strategy achieved thus far, though additional complications related to 
immune reaction and clearance of the delivery vehicle must be taken into account.(5) 
Numerous approaches have been attempted to shield viral particles from the immune 
system while maintaining transduction efficiency.(12) One of the most promising 
approaches to localized gene therapy is the use of a matrix to control the release of viral 
gene carriers as well as shield the viruses from immune interaction, termed matrix-
mediated gene delivery (MMGD).(13, 14) By restricting the release of a gene carrier to a 
carefully controlled release rate that can be engineered to be responsive to environmental 
stimuli such as change in temperature, ionic strength, pH, or presence of cellular stimuli 
such as enzymatic degradation we can constrain delivery to a location of implantation in 
a temporally beneficial manner. 
One class of polymers currently investigated for use in MMGD is silk-elastinlike 
protein polymers (SELPs).(15, 16) SELPs are protein polymers composed of repeating 
amino acid motifs derived from natural sources. The two primary structural units are that 
of bombyx mori silkworm silk (GAGAGS) and mammalian elastin (GVGVP) which are 
arranged in a block copolymer fashion.(17) The length and ratio of silk to elastin motifs 
can be manipulated to change the physiochemical properties of the resultant bulk 
material.(18) For certain block lengths and motif ratios SELPs have the unique ability to 
undergo a sol to gel transition at body temperature, allowing for the mixing of bioactive 
agents followed by injection and finally formation of an insoluble gel depot. The 





exhibited in other temperature sensitive gelling polymers though microscopic solvent 
exclusion is possible. Previously, several SELP constructs with varying lengths of silk 
and elastin blocks, namely SELP815K, SELP47K, and SELP415K (Figure 1.1) were 
evaluated for use as a controlled release depot for MMGD.(16, 19) The results of these 
studies clearly showed SELP815K at a concentration of 4% wt/wt to be most effective in 
the treatment of head and neck cancer using a viral carrier together with MMGD. 
 
1.2 Aims and scope of this dissertation 
In order to progress the SELP biomaterials towards clinical usefulness it is vital to 
assess the degradability and eventual resorption of the depot in order to eliminate foreign 
material in a patient following completion of treatment. The central hypothesis of this 
dissertation is that by incorporating matrix metalloproteinase (MMP) degradable 
sequences into SELPs it is possible to manipulate the rate of degradation seen in vitro and 
in vivo in order to work towards a resorbable controlled release depot for use in MMGD. 
The ideal construct will show clear signs of degradation upon incubation with MMPs and 
in animal models while maintaining effectiveness on par with SELP815K 4% in the 
treatment of xenograft solid tumors. To test this hypothesis the following three Specific 



















Figure 1.1: Amino acid sequence of selected silk-elastinlike protein polymers. Note: 







1.2.1 Compare in vivo effectiveness, safety, and degradability 
of silk-elastinlike protein polymers against 
chemically synthesized poloxamers 
The previously established most effective SELP construct for MMGD, SELP815K, 
was compared against a favorable chemically synthesized candidate for MMGD from the 
literature, poloxamer 407 (20), for the expression elongation, tumor size reduction, and 
survivability increase in a xenograft model of head and neck cancer grown in athymic 
nu/nu mice.(21) Further, the safety of MMGD was evaluated in immune competent CD-1 
mice with histological examination of the hydrogel depots at weeks 1, 2, 4, and 12 post-
injection. The hypothesis behind this work was that the highly controlled nature of SELPs 
would be safe and more effective in the treatment of a mouse model of cancer than 
poloxamer 407. Expression elongation was determined using a luciferin-luciferase 
reporter system in conjunction with a real time live bioluminescence imager. Tumor size 
reduction was evaluated using a replication deficient therapeutic adenovirus in 
conjunction with each polymer system and alone within the context of MMGD to solid 
tumors. Survivability increase was assayed utilizing a tumor bearing xenograft mouse 
model. Additional studies were performed using CD-1 immune competent animal models 
to show toxicity profiles of adenoviral delivery from each polymer depot with blood 
counts, blood chemistry, and histological evaluation of the gel depot injection sites 
monitored. These studies showed tumor size reduction, expression elongation, and 
survivability increase using SELP815K at 4% wt/wt when compared to free viral 
injection, poloxamer 407 as a matrix, and a control (no treatment) group. Further, white 





mice compared to poloxamer 407. As predicted, the SELP815K polymer depot was not 
eliminated from the body by 12 weeks postinjection. This finding lead to the synthesis 
and characterization of enzymatically degradable SELPs, described below. 
  
1.2.2 Synthesize and characterize novel matrix metalloproteinase 
responsive analogs of silk-elastinlike protein polymers 
Due to the robustness of SELP815K when used as a controlled release matrix, the 
synthesis of additional novel MMP responsive analogs based on the structure of 
SELP815K was carried out. Each analog was produced by the insertion of a MMP 
degradable sequence, GPQGIFGQ (single amino acid code used), into either the silk 
region, termed SELP815K-RS5, or the border region between silk and elastin blocks, 
termed SELP815K-RS1, to complement the previously synthesized analog with 
degradable sequence inserted into the elastin units, termed SELP815K-RS2 (Figure 1.2). 
The amino acid sequence chosen was selected for its ability to be readily digested by 
MMP-2 and MMP-9, both of which are overexpressed in many solid tumors including 
head and neck cancer. By inserting the degradable sequence within each of the structural 
units of the SELP815K monomer, we were able to directly determine the effect on 
physicochemical properties of each insertion site. Each polymer was screened for the 
minimum gel forming concentration, swelling ratio, soluble fraction release, rate of gel 
formation, and stiffness of hydrogels. As expected, SELP815K-RS5 with an insert in the 
silk blocks had greatly diminished robustness and physiochemical properties that made it 
unsuitable for use in controlled release. SELP815K-RS1 and SELP815K-RS2 were 















Figure 1.2: Single letter amino acid structures of SELP815K, SELP815K-
RS1, SELP815K-RS2, and SELP815K-RS5 with graphical representation of 







concentration and diminished mechanical properties. In order to rectify these effects, a 
physical conditioning treatment was devised using high shear force by driving polymers 
in solution through a needle valve at 17,000 psi. Following physical conditioning all 
polymers experienced decreased minimum gel forming concentration and increased 
mechanical properties allowing all constructs to proceed as depots for MMGD. The 
physical conditioning step likely removed semistable secondary and tertiary structures 
from single polymer strands leading to a more robust hydrogel network with greater 
intermolecular interaction. 
 
1.2.3 Assess in vitro and in vivo degradability and effectiveness 
of matrix metalloproteinase responsive analogs 
of silk-elastinlike protein polymers for use in 
matrix mediated gene delivery 
Once the physiochemical characteristics of each polymer construct, SELP815K-RS1, 
SELP815K-RS2, and SELP815K-RS5 were confirmed following physical conditioning, 
the application of these matrices to MMGD was warranted. Before in vivo application the 
degradability of each polymer was tested as soluble, single stranded polymers and as a 
hydrogel network. Incubation of SELP815K with 40nM MMP-2 resulted in little 
degradation to soluble polymers over 120 min while all MMP-responsive SELP 
constructs displayed near complete digestion by 60 min. Hydrogel incubation with 40nM 
MMP-2 over 14 days resulted in increased digestion to all polymers as measured by 
soluble fraction release; however, SELP815K-RS5 only released a maximum of 11% 





cleavable insert within the silk block which is known to form stacked beta-sheets. This 
showed the degradability could be influenced by insert location within the polymer 
backbone. Following these studies, testing of each construct in a mouse xenograft model 
of head and neck cancer revealed that higher weight percent, namely SELP815K-RS1 
and SELP815K-RS2 at 8% wt/wt, was necessary to achieve adequate tumor size 
reduction and survivability increase as compared to SELP815K 4%. Further evidence of 
in vivo degradation was found in the histological evaluation of injection sites. These 
samples displayed an apparent ability of the tumor tissue to invade into the gel depots in 
all MMP-responsive SELP constructs, while SELP815K remained intact, limiting 
invasion and degradation by the tumor tissue. Angiogenic sprouting was also observed in 
MMP-responsive SELP gels suggesting vasculature remodeling is possible within these 
depot systems; this has not been observed in SELP815K. The ability of SELP815K-RS1 
and SELP815K-RS2 to degrade in vivo without losing performance as a controlled 
release depot for MMGD represents a step towards a bio-resorbable localized gene 
delivery system. 
 The following body of this dissertation covers the work necessary to accomplish 
these aims within the scope stated above. A literature background representing a broad 
space including head and neck cancer, MMPs, gene therapy, and recombinant polymers 
is presented in Chapter 2 with parts published elsewhere.(22) Chapters 3(21), 4(23), and 
5, detail the methods, results, and discussion thereof required to complete Specific Aims 
1, 2, and 3, respectively. Following the body of work, Chapter 6 is focused on 






more broad application of SELPs to other human diseases. The appendix contains 
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The gene therapy of cancer represents a prime target for the development of new 
treatment paradigms that surpass currently used treatments in efficacy while also 
minimizing toxic effects to the patient. Unfortunately, effective strategies for delivering 
genes efficiently to neoplastic tissue which improve patient outcomes do not currently 
exist. The careful use of viral mediated gene therapy in these cases may represent the best 
path forward when combined with a system capable of limiting the impact of foreign 
biological material on the rest of the body. Pairing a polymer system capable of 
localizing viral vectors to the neoplastic region, while also shielding the carriers from the 
consequences of interaction with the host immune system is prudent in this case. The 
polymer system should first and foremost be safe. Its use should cause no additional harm 
to the patient, degrade into biologically compatible fragments, leave no material behind 
after treatment, and not exacerbate the cancer attempting to be treated. Secondly, the 





size, swelling ratio, release rate, and physical characteristics, it will be possible to 
engineer a repeatedly efficient system with predictable results. Lastly, an ideal system 
will be able to adapt to its microenvironment and react to changing aggressiveness of the 
disease being treated. By satisfying all these requirements it will be possible to tailor the 
system to the disease target and stage, resulting in more favorable patient outcomes. 
 
2.2 Head and neck squamous cell carcinoma 
Head and neck squamous cell carcinoma (HNSCC) is commonly defined as a 
malignancy of the epithelial lining arising from squamous cells primarily associated with 
the pharynx, oral cavity, or larynx.(1) Additional sites of malignancy are possible but 
significantly rare. Head and neck cancers account for approximately 3% of all cancer 
cases diagnosed in the United States with an estimated 52,000 men and women diagnosed 
in 2012.(2, 3) The primary risk factors associated with the development of HNSCC 
include tobacco use, alcohol use, and human papilloma virus (HPV) infection.(4, 5) Up to 
75% of HNSCC cases can be traced back to the use of alcohol, tobacco, or both.(6) 
Currently HNSCC cases caused by HPV, particularly HPV-16, are on the rise while cases 
caused by other factors are falling, possibly due to cultural influence lowering the 
incidence of tobacco use in younger generations.(7) Additional minor contributors to the 
rate of incidence include poor oral hygiene(8), occupational exposure to carcinogens(9), 








2.2.1. Current treatment of HNSCC 
State of the art therapy for HNSCC typically includes surgical resection of the 
affected area, radiotherapy, and chemotherapy.(1, 11, 12) Specific treatment is dependent 
on many factors including site of malignancy, disease stage, and practicing clinician’s 
preferences; however, it has been found that multiple treatment modalities used together 
often result in more positive outcomes for patients.(13) Aggressive treatment of late stage 
resectable tumors using surgery and adjunct therapies including radiation and 
chemotherapy can result in a 5-year survival rate of up to 50%. However, only 
incremental improvements to survival rates have been made in the past several 
decades.(14)   
While prognosis of earlier stage malignancies can be quite positive, the primary 
modes of treatment also lead to significant patient morbidity. Aggressive surgical 
resection is often necessary to improve survival rates due to the typically invasive nature 
of tumors resulting in poorly defined borders. The improved survival rates come at a 
detriment to quality of life due to removal of bordering healthy tissues which are critical 
for performing daily activities such as breathing, chewing, and swallowing.(15) Removal 
of these tissues in the head and neck can also result in heavy scarring and disfigurement 
of the patient in a culturally significant and exposed region, forming a social stigma for 
the patient and impacting quality of life.  
Although the removal of physiological structures in surgical resection is a direct 
cause of patient morbidity, adjuvant and primary radiotherapy, which uses ionizing 
radiation to directly damage cellular DNA also has undesirable side effects on healthy 





vomiting, epithelial damage, mouth sores, throat sores, stomach sores and ulcers, tissue 
edema, and infertility. In the long term, exposure to therapeutic ionizing radiation can 
also lead to fibrosis, epilation, lymphedema, secondary malignancies, and heart 
disease.(16) Typical administration of radiation is accomplished with multiple beams 
used in distinct tracts that intersect at the malignant site. This approach allows for a 
compounding dose in the neoplastic tissue while minimizing healthy tissue exposure.(17)  
Commonly radiotherapy is paired with additive or synergistic chemotherapeutic 
agents which also have undesirable side effects on healthy tissue due to systemic 
administration and damage to vital cellular components. Among the agents currently used 
are platinum based structures, fluorouracil, and docetaxel.(18, 19) These agents have a 
myriad of toxic effects including nephrotoxicity, neurotoxicity, cardiotoxicity, 
myelosuppression, nausea, vomiting, ototoxicity, and alopecia. (20-22) In addition to 
direct DNA damaging chemotherapeutic agents, certain receptors have also been 
targeted, primarily among them epidermal growth factor receptor (EGFR), which is up 
regulated in a number of cancers and is related to cell proliferation. Drugs such as 
cetuximab and lapatinib target this receptor directly and have also shown some benefit; 
however, elimination of the malignancy using only these drugs is rare.(23) Due to this 
they are commonly used in combination with the above mentioned DNA damaging 
agents. Further, these drugs have their own potential toxic effects including pulmonary 
toxicity, cardiac toxicity, anaphylaxis, and severe dermal side effects.(24, 25) As with 
many chemotherapeutic agents, the most effective agents for treating HNSCC are dose 
limited by their toxic side effects. Attempts have been made to reduce or eliminate these 





the chemotherapeutic interaction with healthy tissues and confine action more closely to 
neoplastic sites.  
 
2.3 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are zinc dependent proteases known for their 
activity on extracellular matrix proteins including collagen, elastin, and gelatin; however, 
they are also known for their catalytic ability on a number of other molecules important 
for cellular function.(26) MMPs exist in equilibrium with tissue inhibitors of 
metalloproteinases (TIMPs) to form a feedback loop and prevent excessive activity. 
Unlike many other endopeptidases, MMPs require the presence of a metal ion cofactor to 
affect function. More recently the role of MMPs in invasion and metastasis of cancer has 
become a topic of great interest, and in several studies MMP levels have been correlated 
to invasive and metastatic behaviors of tumor cell lines, though the translation of this 
correlation into in vivo models and patients has been more problematic.(27) Additionally, 
MMPs are known to be overexpressed in a variety of tumor types which has led to 
interest in the enzyme family for the treatment of cancer.(28) 
 
2.3.1 Role of MMPs in cancer 
Due to the role of MMPs in microenvironment modification including the 
degradation of extracellular matrix components, biological molecule activators, and 
expression inducers, these enzymes have been studied extensively to determine their 
exact function in cancer proliferation, invasion, angiogenesis, and metastasis. In some 





induction of neighboring stromal cells such as fibroblasts through the secretion of growth 
factors and cytokines is possible. While structurally conserved, MMPs are a functionally 
diverse class of molecules, and many distinct mechanisms of microenvironment 
manipulation have been elucidated.(29)  
First, the degradation of extracellular matrix and basement membrane necessary for 
removal of physical barriers holding cells in place is postulated to be primarily 
accomplished by MMPs. Similarly, the mechanisms of cancer invasion into normal tissue 
require the removal of cell-cell and cell-extracellular matrix (ECM) interactions 
accomplished through the activation of membrane bound and secreted MMPs. MMP-14, 
MMP-2, and MMP-9 have been shown to be primary players in this role and help to 
facilitate cell invasion from the primary site of carcinogenesis.(30) This degradation also 
has consequences on the migration of cancer cells through the exposure of basement 
membrane sites and integrins which promote migration and adhesion.(31) Also of 
importance is the influence of MMPs on the epithelial to mesenchymal transition (EMT), 
which leads to increased ability to migrate and invade distant sites from the primary 
tumor site. Much of the influence of this transition is derived from the cleavage of 
adherence points and activation of signaling molecules such as transforming growth 
factor beta (TGF-β).(32, 33) 
MMPs have also been shown to impact cellular proliferation of cancerous cells 
through their interaction with membrane bound precursors of important growth factors. 
The liberation of insulin-like growth factors (IGFs) and EGFR ligands from their 
membrane bound state by MMP 1, 2, 3, 7, 9, 11, and 14 lead to an increase in cellular 





of the effected cells.(34, 35) Further, the degradation of ECM, which can liberate cellular 
adhesion sites known as integrins, leads to a signaling cascade involving cadherin and 
catenin promoting further cellular proliferation.(29) Other signaling molecules important 
for proliferation such as TGF-β can be produced through the interaction of the inactive 
proform with MMPs 2, 9, and 14 through their endopeptidase activity.(36) 
As with cellular proliferation, apoptosis mechanisms can also be impacted by 
overexpression of MMPs. One mechanism of apoptotic resistance is through the cleavage 
of Fas ligand by MMP-7. Fas ligand is a transmembrane protein that interacts with Fas, a 
common apoptosis signaling receptor. By cleaving Fas ligand, the Fas apoptosis pathway 
is inhibited.(37) Additional inhibition can be induced to other apoptotic pathways through 
the activation of EGFR and IGF receptors, which can trigger cascades to broadly inhibit 
apoptosis in addition to promoting cellular proliferation as described above. (38) 
Angiogenesis is another important process harnessed by cancerous cells to promote 
tumor growth and migration. This process can be positively or negatively affected by the 
overexpression of MMPs, and once again the key enzymes involved include MMPs 2, 9, 
and 14.(39) The initial degradation of the physical barriers such as ECM to angiogenesis 
has been covered above, but several other factors are also involved in the modulation of 
angiogenesis by MMPs. In order for effective sprouting of new blood supply, important 
growth factors are also necessary in addition to removal of physical barriers. Vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are two of 
these important molecules that are produced by MMPs from the degradation of ECM.(40-
42) This balance is, however, carefully controlled as the generation of degradation 





components.(41, 43) Due to these competing conditions the tumor is capable of 
influencing its microenvironment to lead to favorable conditions for growth and 
angiogenesis. 
While MMPs have been shown to be important in the progression of cancer, they 
have also shown to influence the survival of cancerous cells through the evasion of the 
immune system. Several MMPs have been implicated in the removal via proteolytic 
cleavage of immune markers important for recognition by natural killer (NK) cell 
neutrophils, and macrophages while also suppressing the local proliferation of T-
lymphocytes via interleukin receptor cleavage.(44, 45) The release of TGF-β as 
referenced above by MMP degradation similarly has T-lymphocyte suppression activity 
that leads to increased ability to evade normal immune response.(46) 
Some confounding results have also been seen in MMP knockout models in mice. 
Research has shown that the knockout of MMP-9 can act as a protectant against 
cancerous legion establishment as exhibited by a lower incidence of cancer appearance 
under the same carcinogenic conditions as wild type. Interestingly, in the same study 
cancers that were formed in MMP-9 knockout conditions showed significantly more 
aggressive behavior than in wild type mice.(47) As with all research on MMPs, results 
drawn at any scale other than patient samples must be taken with caution as evidence 
does not always scale to the next highest order animal. 
 
2.4 Gene therapy 
The possibility of correcting the genetic cause of disease has drawn researchers to 





including cancer.(48) Through the delivery of exogenous nucleic acids to cells the 
possibility of “drugging” any known genetic sequence becomes possible. With all of its 
promise, gene therapy is confronted with a number of obstacles to its widespread clinical 
use. The primary challenge that has captivated the field since its inception is the safe and 
effective delivery of a therapeutic nucleic acid sequence to the target cells while avoiding 
potentially harmful effects to nontargeted cells and organs and avoiding possible immune 
implications.(49) Methods for accomplishing this involve the use of genetically 
engineered viruses as nucleic acid carriers (50) or nonviral gene carriers that can complex 
with or condense DNA in a myriad of different approaches.(51) 
 
2.4.1. Cancer gene therapy 
Fundamentally cancer is a genetic disease resulting from the malfunctioning of one or 
more pathways leading to the uncontrolled proliferation of cells. As genetic defects are 
the root causes of cancerous tissue, the approach of modifying the malfunctioning genes 
or introducing new genes to control growth and eliminate the diseased tissue follows. 
Many approaches have evolved in cancer gene therapy existing in broad categories that 
are at times overlapping. Typical classifications include suicide gene therapy,(52, 53) re-
establishment of tumor suppressor genes,(54, 55) oncolytic viruses, and anti-angiogenesis 
gene targeting.(56, 57)  
Suicide gene therapy involves the introduction of a gene or set of genes which cause 
direct killing of the infected cell through apoptosis. Classically, suicide gene therapy 
suffers from the need to transfect every cell in a tumor mass with the gene carrier of 





with tumor suppressor genes.(58) A modification of this approach known as gene-
directed enzyme-prodrug therapy allows for the transfection of nucleic acids encoding an 
enzyme that converts a nontoxic prodrug into a cytotoxic metabolite within transfected 
cells. This approach was selected due to the benefit of transport of the cytotoxic 
metabolite to neighboring cells, which allows for a lower amount of tumor transfection to 
lead to higher cell killing percentages known as the bystander effect.(59) One example is 
the herpes simplex virus thymidine kinase (HSVtk)-ganciclovir (GCV) system.(60) In 
this case HSVtk converts ganciclovir into ganciclovir monophosphate. The 
monophosphate form is triphosphorylated by cellular machinery and competitively 
incorporated into DNA in place of deoxyguanosine triphosphate during synthesis leading 
to chain termination and apoptosis. (59) Another prominent GDEPT system is cytosine 
deaminase with the prodrug 5-fluorocytosine. In this case the cytosine deaminase enzyme 
is sourced from one of several bacterial hosts that converts the nontoxic prodrug 5-
fluorocytosine into 5-fluorouracil, a well-known chemotherapeutic drug.(61) 
The establishment or re-establishment of tumor suppressor genes in tumor tissues is 
another popular approach to cancer gene therapy. In many cancers the mutation or 
inactivation of tumor suppressor genes allows for genetic damage to go unchecked and 
the beginnings of cancerous tissue to take root. The prime example of inactivated tumor 
suppressors is p53; p53 is a gatekeeper protein for DNA damage allowing for DNA repair 
mechanisms to take action or inducing apoptosis in cells with DNA damage that cannot 
be effectively repaired.(62) Mutations in p53 are present in almost 50% of all tumors in 
humans, and as such are an attractive target for tumor suppressor related gene 





establishment of DNA damage checkpoints leading to apoptosis in cancerous cells while 
having no off target effects in healthy cells due to the endogenous p53 already 
present.(64) One problem with wild type p53 transfection as a tumor therapy is the 
dominant negative effect in which a mutated p53 can inactivate wild type p53. This effect 
is commonly associated with some mutated p53 leading to a less effective therapy where 
translocation or null expression is not the mutation type.(65) 
As opposed to suicide gene therapy, or tumor suppressor transfection, oncolytic 
virotherapy focuses on the ability of the gene carrier to replicate similarly to a wild type 
virus eventually leading to the lysis of the host cell.(66) Often these carriers are 
engineered to selectively replicate only in tumor tissues through the use of tumor specific 
promoters such as hypoxia responsive elements or specific genome deletions which only 
allow viral genome replication under cancerous conditions.(67) These modifications 
prevent normal virulence of the carrier in noncancerous tissues and restrict therapeutic 
lytic effects only to tumor tissues. In some cases classic suicide gene therapy is paired 
with an oncolytic virus carrier to attempt a double effect on cancerous tissues and is 
expected to produce better patient outcomes.(68) The first oncolytic virus therapies in the 
form of both engineered oncolytic vaccinia virus and adenovirus are starting to be 
approved abroad for human use and are currently in clinical trials domestically.(69, 70) 
Central to anti-angiogenesis gene therapy is the attempt to inhibit the ability of 
neoplastic tissue to recruit new avenues of blood supply to allow for further growth and 
progression. By inhibiting the angiogenesis process it should be possible to slow or stop 
the growth of the targeted tumor.(71) Many approaches involve targeting VEGF and the 





development of new vasculature. Anti-angiogenesis therapy of all kinds including small 
molecule, antibody, and gene therapy has unfortunately thus far faced difficulties in the 
clinical setting due to the complexities of the angiogenesis process such that complete 
inhibition of a single pathway will not necessarily stop angiogenesis, and even the 
complete blockage of angiogenesis does not lead to tumor regression. (72) As such, anti-
angiogenesis therapy must be paired with other therapies. There have also been some 
studies indicating the lack of blood supply to a tumor may increase the metastatic and 
invasive potential.(73) With all strategies of cancer gene therapy, the efficient delivery of 
nucleic acids to neoplastic tissue is the primary hurdle to be overcome for the effective 
translation to the human condition. 
 
2.4.2 Nonviral gene delivery 
Nonviral gene delivery relies primarily on chemically synthesized vectors able to 
carry genetic material into target cell types. Nonviral gene carriers must be able to fill 
several roles in order to act effectively including shielding nucleic acid cargo from host 
degradation and immune recognition, efficient transit through extracellular barriers, 
efficient transduction into the intracellular compartment, and low toxicity.(74) Many 
attempts have been made with increasingly complex systems to achieve the above stated 
goals. The primary archetypes of nonviral gene delivery vectors consist of polymers, 
lipids, polypeptides, and nanoparticles.(75, 76)   
The polymer subclass of nonviral gene delivery vectors typically embody at least one 
cationic component capable of condensing with negatively charged nucleic acids to form 





promising results in their ability to efficiently transfect large amounts of nucleic acids; 
however, the polymers used also resulted in significant toxic effects including 
complement activation in vivo.(77, 78) More recent work has focused on reducing the 
toxicity of the cationic polymers in one such instance by grafting poly(ethylene glycol) 
onto cationic polymer complexes. (79, 80) While this approach resulted in less toxicity, 
the shielding effect also showed significantly decreased cellular transduction and as a 
result lower gene expression was achieved. Poly(methacrylate) and cyclodextrins have 
also been used as polymeric nonviral gene carriers; however, these polymers have faced 
similar challenges in balancing transfection efficiency against cytotoxicity.(81-83) 
Lipid utility in gene delivery is somewhat limited to the formation of liposomes for 
the transfer of nucleic acids into cells. N-(1-2,3-dioleyloxypropyl)-N,N,N-
triethylammonium (DOTMA) and 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine 
(DOPE) alone and in conjunction were the earliest lipid gene carriers used since the early 
1980s. Liposomes formed from these polymers showed high transfection efficiency; 
however, much like the cationic polymers discussed above, increasing concentrations of 
lipids also lead to an increase in the toxicity of the treatment.(84, 85) Arguably the most 




is a nonviral cationic liposome-based gene delivery platform composed of a mixture of 
DOPE and 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-
propanaminium trifluoroacetate (DOSPA).(86) This platform has been repeatedly shown 
to have high transfection efficiency and is commonly used for the in vitro transfection of 
cells for studies utilizing gene transfer.(87) Unfortunately, in vivo testing of the reagent 





Other liposomal delivery systems typically used modifications of the above, in some 
cases increasing transfection efficiency, but still not able to reach a high enough 
transfection to cytotoxicity ratio for use in vivo.(89) 
Polypeptide application for delivery of nucleic acids is not only regulated to use as a 
bulk material, but also represents unique strategies utilizing synthetic motifs and those 
borrowed from nature to increase transduction efficiency in delivery systems. Many bulk 
systems use a cationic block composed of poly-lysine to complex and condense with 
negatively charged nucleic acids although other motifs are possible.(90) More 
interestingly, a number of peptide sequences capable of assisting entry of nucleic acid 
carriers into cells have been used and are termed cell penetrating peptides (CPP).(91) 
Widely used natural examples included INF from the influenza virus(92) and the Tat 
peptide from the human immunodeficiency virus (HIV).(93) In the synthetic realm the 
KALA peptide has been designed as an alpha helical structure that can complex with 
DNA to aid in gene transfection.(94) Beyond the physical means of increasing 
transfection efficiency, short polypeptides are also often used as a means for receptor 
based targeting such as the case with the RGD peptide known to interact with certain 
integrins.(95)  
Nanoparticles represent a diverse class of delivery systems comprised of a variety of 
materials including polymers, proteins, inorganic media such as silica and gold, carbon, 
and blends thereof. As such, there is some promiscuity of the classes with some 
polymers, lipids, and peptides forming nanoparticles.(96) Often nanoparticles are 
multifunctional, borrowing the favorable parts of each gene delivery vehicle in an attempt 





systems face similar challenges requiring high transfection efficiency while limiting the 
toxicity to the target cells. One benefit of nanoparticles often exploited particularly for 
the delivery of nucleic acids to tumors is the enhanced permeability and retention (EPR) 
effect in which complexes of the general size range of 30-100nm preferentially 
accumulate into tumor tissue postulated to be due to the leaky vasculature often present in 
neoplastic regions.(98) 
 
2.4.3 Viral gene delivery 
Despite advances in nonviral gene delivery there has yet to be a carrier designed that 
can match the high infectivity with low cytotoxicity that viral vectors commonly exhibit, 
as discussed above. Viral vectors take advantage of evolutionary pressure throughout the 
course of biologic history leading to extremely efficient gene transfer agents without 
compromising the integrity of the infected cell likely due to the avoidance of high 
positive charge density necessary to condense DNA in nonviral systems.(99) Despite 
these advantages there have been very few worldwide approvals for the use of therapeutic 
viruses in human subjects due to issues including immune clearance, low transfection 
levels of target tissue, off target transfection, and short transgene expression.(100) 
As of 2014, of the 2076 clinical trials utilizing gene therapy, over 65% used a viral 
vector in order to transfer genes of interest into target cells.(101) The most common viral 
vectors used included adenovirus, retrovirus, vaccinia virus, pox virus, adeno-associated 
virus, and herpes simplex virus. Each of these viral types has advantages and 
disadvantages that must be tailored to indication, expression longevity, and immune 





Adenoviruses (Ad) were the most common virus used among gene therapy clinical 
trials patients accounting for 22.8% of the total.(101) Ad are nonenveloped double 
stranded DNA viruses which are structurally defined by their capsid construction 
composed of 240 hexon and 12 penton protein bases.(102) These viruses carry 36-40 kb 
of DNA and rely on receptor mediated endocytosis through Coxsackievirus and 
adenovirus receptor (CAR) interaction with fiber knob proteins along with penton base 
interaction with integrins.(103) Adenoviruses do not integrate their payload into the host 
genome, and as such result in transient gene expression lasting 1-2 weeks. Somewhat 
problematically humans tend to have high immunity to the majority of Ad serotypes 
which leads to quick clearance from systemic circulation and possible immune response, 
both of which are detrimental to the efficacy of treatment and can be dangerous to the 
patients’ health.(104) In addition, Ad will infect any tissue expressing CAR receptors, 
though density of these receptors can vary widely even in closely related tissues and 
cancers of the same tissue type.(105) Despite these drawbacks the only two approved 
gene therapy treatments for cancer are Ad based systems.(70) 
Retroviruses including lentivirus account for the second highest amount of gene 
therapy clinical trials at 23.3%.(101) Retroviruses are enveloped viruses with a capsid 
inside a phospholipid vesicle sourced from host cellular membrane. These viruses 
typically contain two identical 7-10kb genomes of single stranded RNA that integrate 
into the host genome for long-term or permanent gene expression.(106) While integration 
can lead to favorable expression profiles, it can also disrupt genes important for cellular 
function and result in the spontaneous generation of cancer. This was the case in patients 





disorder making patients completely unable to fight infection, where over 40% of the 
patients developed T-cell acute lymphoblastic leukemia (T-ALL) following 
treatment.(107) 
Adeno-associated viruses (AAV) accounted for nearly 5% of gene therapy trials to 
date.(101) AAV is a type of virus known as a helper virus that is unable to replicate 
without co-infection of cells with adenovirus or herpes simplex virus.(108) These viruses 
are physically smaller than most other viruses with a diameter on the scale of 25nm and 
are only able to contain up to 4.7kb of single stranded DNA.(109) Interestingly, despite 
widespread human immune response to AAV serotypes, cytotoxic T-cell response 
following administration is typically weak allowing for longer-term expression and re-
administration of the viral carrier.(102) The prototypical examples of AAV delivery of 
genes encompass treatment to muscle, eye, and brain tissue.(110-112) 
Other viruses are also utilized including vaccinia virus, pox virus and herpes simplex 
virus. These three vehicles combined have been used for 15.2% of gene therapy clinical 
trials for a wide variety of indications and targets.(101) Recently, vaccinia virus has 
garnered much attention as an oncolytic vector capable of targeting and killing cancer 
cells.(113) One trial of this for melanoma patients showed a response rate of up to 75% 
and has spurned onward more clinical trials recruiting for treatment of a variety of 
cancers.(114) 
While viral gene carriers exploit the highly evolved transfection efficiencies of 
viruses, they also suffer from the host immune system’s ability to combat the infectious 
threat.(104) Several approaches to minimize the systemic effects of viral carriers have 





carrier to suppress its activation of the immune system, has unfortunately resulted in a 
reduction in transfection efficiency.(115) A similar approach which utilizes charge-
charge interactions with viral carriers in addition to chemical modification with targeting 
ligands has shown much increased efficiency and targeting for systemically administered 
viral constructs.(116, 117) Another approach, administering the viral carrier in a localized 
manner to avoid systemic exposure and off target transfection, has yielded less than 
optimal results due to the propensity of the viral carrier to disseminate from a local 
injection site when unconstrained.(118) A combination of the two approaches has led to a 
promising solution, i.e., matrix mediated viral carrier delivery. The viral carrier is 
injected in a biomaterial that limits its exposure to the immune system and limits its 
dissemination from the injection site. Furthermore, the specific physical and chemical 
characteristics of the biomaterial can be used to control the release of the viral carrier to 
the surrounding tissues in a localized and sustained manner.(119)  
 
2.5 Recombinant polymers for controlled release 
Natural proteins have a predesigned function eliciting a specific cellular response. 
This automated behavior is resultant of their primary amino acid sequence that dictates 
folding patterns and architecture, which in turn commands function.(120) Understanding 
the central dogma of molecular biology has opened avenues in biomaterial design, 
particularly engineering recombinant protein polymers for new applications in biological 
systems. These recombinant polymers are synthesized by harnessing the protein synthesis 
machinery of cells through genetic engineering and DNA manipulation.(121-126) The 





grounded on function. DNA sequences of diverse species may be combined or synthetic 
sequences using noncanonical amino acids like p-fluorophenylalanine or 
selenomethionine may be introduced, creating novel functions demanded by the chosen 
application.(127) 
The early 1970s encompassed pivoting work by biochemists including Lobban, 
Kaiser, Berg, and Khorana who developed biochemical methods for inserting new 
genetic material in pre-existing DNA of a bacteriophage, paving the way for chemical 
syntheses of genes and recombinant DNA technology.(128-131). One of the earliest 
works describing synthesis of a recombinant polymer in a biological system was by Doel 
and coworkers in 1980 where a defined DNA sequence was made via phosphotriester 
methodology and subsequently cloned into E. coli using plasmid vectors with 
controllable promoters.(123) E. coli expression yielded a simple polymer of 
phenylalanine and aspartic acid that is enzymatically degradable.(123) Synthetic methods 
of more complicated polymers composed of repetitive copolypeptides began to be 
established in the late 1980s and early 1990s including work by Fournier, Tirrell, and 
Cappello.(121, 124, 127, 132-134) Both chemical synthesis and genetic strategies were 
explored. McGrath et al. described both techniques to create copolypeptides [-(GlyAla)3-
 GlyProGlu-]n, first via classical solution phase methods, yielding a polydisperse product 
of average molecular weights less than 100,000 Da, followed by recombinant DNA 
methods where chemically synthesized oligomers were self-ligated resulting in multimers 
subsequently incorporated into expression plasmids with appropriate translation signals. 
E. coli expression of the plasmids yielded a monodisperse product.(124) This work is a 





Although, synthetic polymers have been designed in parallel with recombinant 
polymers for similar applications, there are several advantages to recombinant polymers 
over their chemically synthesized counterparts. First, the level of control by nature’s 
cellular machinery to make macromolecules remains unsurpassed.(120) When 
recombinant polymers are made in a biological system, such as bacteria, the product is 
virtually monodisperse in both sequence and size. Each polymer strand is an exact copy 
generated from a DNA template, which was previously designed and transferred into the 
production cell line.(135) This monodispersity can be important in drug delivery 
applications to enable generation of distinct release profiles and determine structure-
function relationships that may not be possible with a statistically defined polymer 
system. Chemically synthesized macromolecules cannot match this precision especially 
in more complicated and longer chain length polymers, which often generate statistical 
distributions of polymer lengths. Figure 2.1 depicts general recombinant protein 
engineering methodology, which begins with design of the amino acid sequence for the 
desired product. The DNA sequence is synthesized using solid phase techniques. Often, 
the final product consists of repeats of a single sequence; therefore a small oligomer is 
synthesized followed by a multimerization process and enzymatic ligation into a DNA 
plasmid vector. Multimerization can be considered a polycondensation event where 
designed sticky ends of the oligomers bind, creating random length multimers. Once the 
multimers are ligated into the vector, a host cell, often a bacterium like E. coli, is 
transformed and grown as individual colonies for plasmid screening. The screening 
allows determination of multimer size and consequently isolation. Isolated plasmid is re-

















ensues.(120, 127) Expression vectors are designed to have a switch, such that the protein 
is only expressed at high bacterial density. Switches may be chemically or temperature 
induced. Premature protein synthesis will hinder bacterial growth and product yield will 
be low. (120) 
Second, recombinant polymers are often biodegradable as they are constructed of 
simple amino acid residues and degrade into small peptides or amino acids.(136) Third, 
recombinant polymers can be systematically altered in order to generate libraries of 
potential candidates or investigate the exact role of individual components of the polymer 
system on properties important for controlled release such as mechanical integrity, 
bioactive agent release, biorecognition, degradation and elimination. The Urry group 
systematically approached the synthesis of peptide-based polymers to understand how 
different biophysical properties change with methodical change in polymer 
sequence.(137) They began by constructing a basic gene unit encoding (GVGVP)10 and 
building concatemer genes with varying repeats of the monomer unit, creating 
macromolecules greater than 100,000 Da. This work, along with other work using 
sequential poly peptides synthesized chemically, generated a library of polymers relating 
structure to function whereby strategic changes in the nature and sequence of amino acid 
residues altered physicochemical properties of the polymers such as pH and temperature 
sensitivity and solubility.(136-138) Several classes of recombinant polymers are well-













Table 2.1: Common amino acid sequences and main structural components of 
recombinant polymers discussed in this chapter. ELP: Elastin-like Polypeptides, SLP: 











2.5.1 Elastin-like polypeptides 
Elastin-like polypeptides (ELPs) in their most basic form are recombinant polymers 
comprised of repeats of the amino acid sequence valine-proline-glycine-X-glycine 
(VPGXG) where X represents any amino acid except proline as found in mammalian 
tropoelastin.(139-142) This repeating sequence forms a soluble β-helical structure at 
lower temperature, which reversibly collapses into an insoluble aggregate above a critical 
temperature termed the inverse transition temperature (Tt). The Tt can be tuned using 
ionic strength in solution.(143, 144) The number of repeats and the guest residue X can 
also be used to shift the transition temperature and impact other sensitivities such as 
electromagnetic fields,(145) ionic strength,(144) and pH.(146) The biocompatibility of 
ELP in its basic form using generic biological tests was extensively studied by Urry et 
al.(147) Their results indicated excellent biocompatibility, therefore establishing ELP as a 
parent biomaterial for development of a wide range of medical applications. Examined 
properties of ELPs in the formation of nanoconstructs and hydrogels are reviewed 
extensively.(142, 144, 148-156) 
 
2.5.1.1 ELP based nanoconstructs 
ELP nanoparticles were first fabricated with the synthesis of ELP di-block 
copolymers with distinct guest residues and block lengths leading to different transition 
temperatures (Tt). As the solution temperature is elevated above the lower Tt, this block 
collapses becoming hydrophobic while the higher Tt block remains hydrophilic. The 
hydrophobic blocks associate to minimize hydration while the hydrophilic blocks form a 





purification of ELPs through reverse phase transition cycling during which ELPs can be 
selectively forced out of solution using varying amounts of salt and heat. This behavior is 
an advantage in the use of ELPs and leads to a much simplified purification compared to 
other recombinant proteins and chemical polymers. ELP micelles have been used in a 
myriad of applications to deliver a wide array of bioactive agents from chemotherapeutics 
such as doxorubicin (158) and geldanamycin (159) to growth factors such as bone 
morphogenetic protein 2 and 14.(160) 
More recently, research efforts have turned to using ELP carriers to increase the 
therapeutic efficacy of clinically relevant drugs by tuning the polymeric structure. One 
method being explored is the use of multiple-stimuli sensitive ELP-based particles 
designed to dissociate in the presence of the lower pH environment within solid tumors; 
this has shown promising results in increasing tumor targeting and penetration of drugs 
and imaging agents.(161) Along with targeted dissociation, multiple locations of drug 
attachment in the hydrophobic core and hydrophilic corona of ELP micelles have been 
achieved by the genetic engineering of a binding protein to the surface of ELP micelles. 
This attachment has shown the ability to increase sequestration and prolong the release of 
the hydrophobic drug rapamycin.(162) In a related study, this construct was shown to 
increase the effectiveness of rapamycin, which suffers from dose limiting toxicity in the 
treatment of the inflammatory disease Sjögren's syndrome.(163) Further, the attachment 
of whole receptors or fragments to the corona of ELP micelles has been accomplished. 
(164) Previously, only short peptide fusions to ELPs had been attempted for targeting of 
micelles due to the potential for structural disruption of the particles.(165) The ELP 





over 100 amino acids and still retain function.(164) This has demonstrated another 
advantage to ELP based nanoconstructs in the ability to add large protein based targeting 
moieties into the innate structure of the nanocarrier without the need for additional 
chemical linking steps. An inverse targeting strategy has also been explored by 
administering chimeric ELP based peptide strands intravenously and heating an area of 
the body, in this case a tumor, above Tt. This led to the assembly and anchoring of 
constructs in the tumor and vasculature termed thermal targeting, which has shown 
success with doxorubicin(166) and radioisotopes for brachytherapy.(167)  
While strides were made in increasing the effectiveness of ELP micelle delivery, 
biodegradation and elimination are also important topics of study. It has now been shown 
that ELP micelles are subject to biodegradation in hepatocytes after uptake as expected; 
however, it appears the micelle structure is protective against some enzymes such as 
collagenase known to degrade ELPs in the soluble form.(168) Efforts were also made to 
form mathematical models to predict the behavior of ELPs in solution and micelle 
formation based on their length and guest residues to allow for a rational design of 
delivery systems tailored to the drug of choice.(169) This mathematical modeling 
approach was also attempted with ELP fusion proteins and has likewise shown 
success.(170) 
Assembly of ELP micelles has traditionally relied on the Tt as described above; 
however, recently other methods of assembly have also been shown. In one such instance 
Tt is bypassed by the conjugation of hydrophobic moieties to soluble ELP strands that 
can trigger assembly into micelles.(171) This assembly is reminiscent of classical 





also been attempted in the intracellular space with some success and has been shown in 
cells transfected with plasmid producing ELPs.(173) This approach could lead to the 
development of intracellular structures or potential organelle targeting.  
ELP polymer hybrids with other materials have been considered for the synthesis of 
more complex nanomaterials. In one case, cylindrical micelles were formed by radical 
polymerization of ELPs and this may be advantageous in drug delivery due to the large 
number of potential sites for functionalization.(174) Combining the monodispersity and 
functional strengths of recombinant polymers with chemical polymerization can yield the 
design and development of a wide array of organized structures. Similar to ELP hybrids, 
the synthesis of multi-armed ELP constructs that consist of an ELP domain fused to a 
fold-on domain that links three individual polymer strands has been achieved.(175) These 
constructs have shown self-assembly into the expected spherical micelles at low salt 
concentrations, but forming elongated rods with an aspect ratio in excess of 10 in higher 
salt concentrations.(176) 
The in vivo quantitative particle tracking of ELPs has been explored with positron 
emission tomography (PET) imaging in combination with 
64
Cu conjugated polymers, as 
pharmacokinetics and tracking the fate of administered drug delivery systems has long 
been a mainstay of preclinical testing. It was shown that the half-life and distribution of 
ELPs did not change based on whether they were assembled into micelle structures, but 
rather wholly depended on the molecular weight of the individual polymer strands. This 
result may show the micelles formed could be unstable in blood and may break into 






Although earlier work had shown convincing biocompatibility of basic ELPs(147), 
newer constructs made from these polymers or modifications thereof need to be evaluated 
individually. Furthermore, architecture of the materials can affect distribution, 
degradation, and elimination. Final biological fate must be determined and quantified, 
particularly long-term responses by the immune system if nanoconstructs made from 
recombinant polymers are to be used clinically. 
 
2.5.1.2 ELP based hydrogels 
ELP hydrogels like their nanoconstruct counterparts are formed of the same basic 
structure of repeats of VPGXG, but often with other modalities designed into the polymer 
backbones to facilitate hydrogel formation. These hydrogels have been formed by several 
distinct mechanisms of varying effectiveness for biologic application. Cross-linking 
strategies including chemical,(178) enzymatic,(179) photo-mediated,(180) γ-
irradiation,(181) and physical assembly (182, 183) have been used. More recently, 
additional methods of cross-linking have been successfully tested utilizing cystine 
residues designed into the polymer backbone. These residues form disulfide bonds 
between strands, reducing the weight percent of polymer needed to form hydrogels 
although an oxidative environment is still required, which is generated using chemical 
agents.(184) Rheological testing of these materials revealed lower storage moduli than 
expected and this was attributed to a low number of elastically active disulfide cross-
links.(185) Additionally, ultrasonication was explored coupled with heating for hydrogel 
formation in GVGVP structured ELPs and subsequent concomitant release of model 





Depot based release of several drugs was attempted including the use of 
proteolytically degraded systems for the delivery of glucagon-like peptides to assist in the 
treatment of diabetes. These peptides were shown to be expressed as a fusion with ELPs 
and released by enzymatic cleavage (187) with activity in reducing blood glucose levels 
up to 5 days after administration. This showcased the ability of ELP hydrogels to 
potentially use single step synthesis of depot and cargo.(188) Similarly, an injectable, gel 
forming ELP-curcumin conjugate for delivery of anti-inflammatory molecules to the 
sciatic nerve showed promise in limiting systemic dissemination of the drug and 
satisfactory release over 4 days.(189)  
Degradation of enzymatically cross-linked ELP matrices was also recently tested by 
subjecting hydrogels to proteolytic enzymes from bacterial and mammalian origin. The 
digestion showed promising results liberating polymer strands from a cross-linked 
network and additionally showed an increase in release of a model protein, enhanced 
green fluorescent protein, upon degradation.(190) With regard to degradation, an area 
that remains to be fully explored includes final biological fate and geometry of digested 
gel fragments that leave the depot location. Moreover, toxicity of ELP conjugated with 
drug must be tested at off-target locations, as there is potential for strands of the network, 
which continue to have a drug attached, to release during degradation. 
 
2.5.2 Silk and silk-like proteins 
While ELPs have a predominantly conserved consensus sequence used in the 
majority of controlled release applications, silk and silk-like proteins (SLPs) have a 





Silk and SLPs have gained favor in the drug delivery and controlled release field for their 
mechanical strength, biocompatibility, and biodegradability. The basic properties of SLPs 
are reviewed extensively elsewhere.(191-195) 
The most common of all silk variants is likely the Bombyx mori silkworm silk fibroin 
consisting of a light 25 kDa chain and a heavy 325 kDa chain. Silk fibroin has been 
widely used for controlled release of drugs and proteins from films, gels, implants, and 
nanoparticles (196-203). While widely used, B. mori silk fibroin is generally extracted 
from natural sources and not synthesized by recombinant techniques. Attempts, however, 
have been made to express other silks such as spider dragline silk from B. mori.(204) 
Alternatively, recombinant silk from two species of spider Nephila clavipes and Araneus 
diadematus are widely mimicked for their favorable properties and due to difficulty of 
isolating them from natural sources. 
 
2.5.2.1 SLP based materials 
Recombinant spider silk based nanoparticles have been successfully fabricated and 
fused with other protein motifs to aid in cellular entry or targeting.(205-207) These 
methods have shown to repeatedly yield condensed protein particles capable of carrying 
drug and gene products. More recently, particles engineered to carry protein drugs have 
been fabricated in an aqueous process and showed colloidal stability over 24 hours at 
neutral pH and low salt; however, pH 5 or increased salt resulted in significant particle 
agglomeration. Lysozyme, as model cargo, showed high loading of almost 30% w/w as 
well as penetration into the nanoparticle in addition to surface association. Release of 






Screening for small molecular weight drug compatibility with SLP nanoparticles has 
also been performed. In this study particles composed of a 48 kDa protein consisting of 
16 repeats of a sequence taken from Araneus diadematus silk protein ADF4 self-
assembled into roughly 330nm particles upon titration with potassium phosphate. These 
particles showed greatest affinity for basic compounds with sufficient hydrophobic 
character to interact with the formed particle structure. Acidic molecules were much less 
tolerated. Model compounds showed sustained release for as long as 30 days, however, 
acidic conditions resulted in increased burst release on day 1, demonstrating potential for 
delivery to the acidic tumor microenvironment.(209) Composites of the ADF4 based 
recombinant protein and classic controlled release materials such as poly(caprolactone) 
(PCL) and polyurethane (PU) were also explored and showed a drastic reduction in the 
Young’s modulus and tensile strength of the material compared to the SLP alone. The 
study also showed changes in release of model drugs based on the addition of PCL and 
PU over 30 days; this indicates a potential for tuning the release of compounds to desired 
rates for a given drug.(210) The mechanical properties of potential SLP based particles 
have been studied using recombinant ADF4 from Araneus diadematus. A remarkable 
mechanical stability was observed with dry particles, but was drastically reduced upon 
hydration. It was also found that the modulus of particles could be tuned by changing the 
length of the expressed recombinant protein and with the addition of cross-linking of 
polymer strands. Most interestingly, changes in mechanical and swelling properties from 
a dry to hydrated state were completely reversible showing feasibility of long-term 





SLP hybrids with cationic blocks have shown utility in tumor targeted delivery of 
plasmid DNA. SLP sequences based on the MaSp1 protein of dragline silk from Nephila 
clavipes together with a 15-lysine residue block and tumor homing peptide have shown 
condensation with plasmid DNA into 100nm particles. These complexes were further 
optimized for size and surface charge. The resultant particles showed low cytotoxicity, 
but also much lower transfection than a lipofectamine control. This demonstrates proof of 
concept, but is in need of further optimization.(212) 
SLPs have been compared to expressed proteins from Nephila clavipes by computer 
modeling. This work showed successful prediction of several key parameters of the fiber 
form and films created from two different SLP analogues such as water contact angle, 
and used predicted degree of beta sheet formation for an indicator of material 
strength.(213) Importantly, time and size scales used for modeling of proteins were not 
matched to real world observations of silk proteins but still provided predictions of 
macroscopic behavior. These findings show the possibility of modeling SLP sequences to 
aid in rational material design in addition to the potential ability to predict structural 
consequences to the addition of de novo sequences in SLPs. Results from this study could 
be the first steps to complete in silico design of protein sequences. 
The utility of wrapping silk from Argiope trifasciata in the preparation of 
nanoparticles has been explored. The aciniform protein AcSp1 investigated showed self-
assembly into nanoparticles of 50nm and 220nm without the appreciable presence of 
monomers left in solution. Particles showed good stability in a range of buffered 
solutions and reportedly had thermal stability past 70° C. Loading of rhodamine B as a 





2.5.3 Silk-elastinlike protein polymers 
Silk-elastinlike protein polymers (SELPs) are block copolymers consisting of amino 
acid repeats derived from B. mori silk (GAGAGS)(215) and mammalian elastin 
(GVGVP).(216) SELPs were originally developed in the late 1980s to early 1990s for a 
variety of indications(217) and typically exhibit a sol-to-gel transition when more than 
two silk blocks are present in the polymer with increasing transition temperature tuned 
based on increasing block lengths.(218, 219) From the original synthesis of SELPs, many 
variants have been developed through the addition of guest residues in elastin blocks and 
altering the length and ratios of the silk and elastin blocks which can be used to alter 
resultant polymer and hydrogel characteristics.(220-225) Detailed synthesis, 
characterization, and biological evaluation of SELPs have been reviewed 
extensively.(118, 152, 218, 219, 226, 227) 
The SELPs initially used for controlled release applications were developed in the 
late 1990s through the 2000s, namely SELP47K,(228) SELP415K,(220) and SELP815K 
(221) (for amino acid sequences see Figure 1.1). These constructs, composed of 4:8, 4:16, 
and 8:16 ratios of silk blocks to elastin blocks per monomer repeat, respectively, with a 
single lysine substituted elastin block (GKGVP) per monomer. They were biosynthesized 
to examine the effects of silk to elastin block ratios, lengths and sequences on the 
physiochemical properties of resultant hydrogels. Tight control over the primary 
sequence of these polymers afforded by recombinant DNA technology was vitally 
important to effectively determine the contribution of each length and ratio of silk and 
elastin to final polymer properties. It was found that altering the composition ratios and 





221, 229, 230) and mechanical strength(220, 221, 231) of resulting hydrogels. These 
findings lead to the ability to tune release of bioactive agents based on size and surface 
characteristics.  
SELPs have been examined for controlled release of markers and bioactive agents 
from 180 Da in the case of theophylline (232) to approximately 110nm particles in the 
case of model polystyrene beads.(233) Low molecular weight substrates under 13kDa 
have often shown fast release from SELP47K at 12 wt% in under 4 hours.(232) By 
increasing the concentration of polymers forming the hydrogels to 20 wt%, 85% release 
of a 500 kDa model dextran was achieved over 10 days and release of a 40kDa dextran 
was achieved over 3 days from SELP47K.(228) Surface charge has also been shown to 
affect release rates from SELP hydrogels with positively charged molecules releasing 
more slowly than negatively charged where positive, negative, and amphoteric analogues 
of rhodamine were used.(234) Gene delivery from SELPs has also been explored. The 
characteristics of plasmid DNA release was first examined and showed highly tunable 
characteristics releasing from 2% to 80% plasmid load over 28 days while DNA 
concentration showed little effect on cumulative release rate.(219, 235) Despite the 
highly controllable release of naked plasmid DNA, this route of gene transfer often lacks 
the efficacy required for most applications and as a result viral release from SELP 
hydrogels has been explored. Delivery of adenoviruses from SELP47K over 28 days 
showed polymer concentration to be the key parameter determining release rate,(236) 
however, release also showed dependence on polymer construct as SELP415K released 
faster than equivalent concentrations of SELP 47K due to the higher elastin to silk ratio. 





polymer network.(237) Consequently, these two parameters, structure and concentration 
of SELPs, can be easily manipulated to tailor release to desired levels. In addition, 
degradation of the hydrogel matrix can contribute to observed release rates with elastase 
based degradation showing up to 40% increase in release of plasmid DNA from 
SELP415K hydrogels.(230) SELP systems were also shown to increase the safety of 
adenoviral administration in vivo while increasing the efficacy of treatment and 
restricting viral load more tightly to tumor tissue than free viral injections.(224, 225) 
Additionally, biocompatibility of SELPs has been evaluated in subcutaneous and 
intradermal injections of SELP47K in guinea pigs. This study showed no local signs of 
reaction that could be considered clinically significant or harmful at 3, 7, or 28 days when 
assayed histologically using hematoxylin/eosin and Masson’s trichrome staining. 
Moreover , cellular penetration into the periphery of the gel depots was observed.(228) 
Work in our lab showed among the SELP analogs studied, SELP815K, with 8 silk 
block and 15 elastin block repeats with an additional lysine substituted elastin unit 
(GKGVP) (Figure 1.1), exhibited the most favorable transfection profile for adenoviral 
delivery to xenograft head and neck squamous cell carcinoma solid tumors (Figure 
2.2).(223, 224) Based on these findings, optimizing SELP815K for delivery was 
performed.(238) Following this work initial synthesis of a more degradable version of 
SELP815K was undertaken by our lab. This led to SELPs with matrix metalloproteinase 
(MMP) degradation sequences designed into the polymer backbone due to the well-
known role of MMPs in tumor lifecycle and invasion.(28, 239-242) MMP responsive 
SELPs were designed and showed an increase in degradation as evidenced by protein 









Figure 2.2: β-galactosidase expression in xenograft tumors injected with adenovirus 
released from SELP47K (47K), SELP415K (415K), and SELP815K (815K) assayed at 













(Figure 2.3).(233)  
The potential mechanism for SELP gelation was examined using polymers with silk 
to elastin ratios of 1:8, 2:8, and 4:8 with distinct silk and elastin block regions afforded by 
tight sequence control and a tyrosine substituted elastin unit (GYGVP) in each of the 
elastin blocks. The constructs termed SE8Y, S2E8Y, and S4E8Y, respectively, with 
similar molecular weights were investigated.(243) Scanning electron microscopy and 
atomic force microscopy showed micelle like structures, which are hypothesized to 
precede gel formation. It was also shown that as the silk component of the polymer is 
increased, the reversibility of association decreases, as assayed by circular dichroism, 
turbidity, and dynamic light scattering measurements.(243) These results demonstrate the 
proposed two-step mechanism for SELP hydrogel formation and also confirm the 
observation of increasing silk character in SELPs results in less reversibility once strands 
become associated. This also demonstrated the importance of tight control over polymer 
sequence as block discontinuity could drastically influence the proposed gelation 
mechanism.  
Furthermore, a SELP polymer with a 2:8 silk to elastin ratio with additional lysine 
substituted elastin unit was subsequently modified with retinal using Schiff base 
chemistry. The resultant retinal-SELP construct showed shifts in optical properties as 
measured by optical polarization spectral analysis; this was hypothesized to be due to the 
innate properties of retinal shifting from a relaxed trans state to a more stressed cis state 
when excited with polarized light. This change in structure could possibly be used to 
impart photosensitive properties to SELP hydrogels for the purpose of drug delivery and 
controlled release.(244) Due to the highly controllable nature of recombinant polymers 
















Figure 2.3: Protein loss (A) and particle release (B) as a result of digestion of 













the ability to precisely control the release of cargo based on concentration, silk to elastin 
ratio and sequence, and degradation properties. Experiments assaying the safety of these 
polymers up to 12 weeks have shown a lack of significant toxicity or immune interaction 
as evidenced in subcutaneous injection in mice, and subcutaneous and intradermal 
injection in guinea pigs,(245) but more complete analysis needs to be done in multiple 
relevant species to show the long-term safety for clinical application.  
 
2.5.4 Recombinant cationic polymers 
Cationic polymers have been explored to transfer genes to mammalian cells, often 
using synthetic polymers such as poly lysine or polyethyleneimine (PEI). The 
development of recombinant cationic polymers (RCPs) has shown promise in correlating 
structure with function in nonviral gene delivery.(246) Bifunctional RCPs were first 
developed in the late 1990s and early 2000s with a system composed of a cationic lysine 
oligomer to condense plasmid DNA coupled to a β-galactosidase derived protein with 
RGD functionalities for targeting cell surface integrins.(247) While providing proof of 
concept, this system lacked an efficient endosomal escape mechanism, and therefore 
sufficient efficacy. Bifunctional RCPs were also synthesized on a cationic oligomer block 
fused to an ELP, but in the absence of an endosomal escape mechanism the system led to 
poor efficiency.(248) Trifunctional biopolymers were then synthesized in an attempt to 
achieve efficient gene transfer from RCPs. These polymers consisted of lysine-histidine 
(K-H) residues with a fibroblast growth factor 2 (FGF2) fusion. As in other constructs, 
the lysine residues condensed DNA while the histidine residues were hypothesized to 





that a random sequence of K-H did not perform as well as distinct blocks of K and H. It 
was also determined that the incorporated H residues were not enough to promote 
efficient escape.(249) Multifunctional RCPs were next synthesized with four parts 
including arginine-histidine R-H domains for nucleic acid condensation and endosomal 
escape, a targeting peptide for delivery, a fusogenic peptide for endosomal escape, and a 
nuclear localization signal for intracellular trafficking. This four domain RCP showed 
increased gene transfer efficiency as compared to previous constructs.(250) This ability 
to stack new functional segments on identical clones of previously synthesized constructs 
is unique to recombinant polymers and represents one of the chief advantages of this 
polymer type. Since each previous construct can be replicated via its DNA sequence with 
near monodispersity, the consequences of insertion of additional segments can be studied 
without worry of batch to batch or molecule to molecule variability. RCPs show this 
advantage leading to stepwise improvement in material properties over time. A review on 
the development of RCPs can be found elsewhere.(246) 
The multifunctional RCPs have been tested in vivo with a gene for thymidine kinase 
used in conjunction with the prodrug ganciclovir for suicide gene therapy. Delivery of the 
construct to xenograft SKOV-3 tumors with resultant tumor knockdown for 3 weeks was 
demonstrated.(251) This in vivo test of the RCPs is an important step past cell studies to 
show the feasibility of the vectors in more complex systems. Multifunctional RCPs have 
been improved with the incorporation of novel domains such as a DNA condensing block 
based on repeats derived from histone H1. This construct showed good transfection 
efficiency, greater than a PEI control in some cases with low associated cytotoxicity in 





release of nucleic acids from carriers that had previously been achieved with other 
cationic condensing recombinant sequences.(253) This study showed low 
immunogenicity and toxicity of the new histone based polymer sections and higher 
release efficiency of nucleic acids, which leads to greater efficacy of treatment in vitro 
and in vivo.  
Work has continued on the endosomal escape mechanism of RCPs with additional 
fusogenic peptides being tested.(254) These fusogenic peptides commonly used for 
endosomal escape were also compared head-to-head in order to determine the potential 
benefit of each sequence in the context of gene delivery from RCPs. Of the five 
sequences tested, a peptide known as GALA consisting of a glutamic acid enriched 
sequence derived from influenza virus hemagglutinin showed the greatest effect with the 
least cytotoxicity. Additionally, these studies showed the versatility of recombinant 
polymers in the evaluation of potential candidates for controlled release. Through 
recombinant DNA technology, virtually identical protein polymer constructs were 
designed and expressed with difference in only one key component, which allowed an 
effective head-to-head comparison and selection of the best candidate.(255) Delivery of 
siRNA has recently been shown to be effective from RCPs as well. A multifunctional 
RCP using similar domains to those shown in the past without a nuclear localization 
signal showed efficient delivery of siRNA to the cytoplasm of cells in vitro and adequate 








2.5.5 Other recombinant protein polymers 
In addition to the body of work briefly reviewed above, there are other avenues that 
are being pursued with recombinant based polymers for controlled release. Collagen as a 
recombinant peptide sequence has been explored, although to a lesser extent than silk 
since collagen can be found from natural sources abundantly, including bovine hides and 
can be easily extracted from these sources. A problem with polydispersity arises if the 
desired collagen is to be a specific uniform length(257), fused with other proteins,(258) 
or a pure form of a specific collagen.(259) In these cases, recombinantly produced 
collagen and collagen-like proteins can be superior to their natural counterparts due to the 
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COMPARISON OF SILK-ELASTINLIKE PROTEIN POLYMER 
HYDROGEL AND POLOXAMER IN MATRIX- 
MEDIATED GENE DELIVERY 
 
3.1 Introduction 
Among the numerous biomaterials investigated for matrix-mediated gene delivery, 
genetically engineered, silk-elastinlike protein polymers (SELPs) have demonstrated 
important potential advantages. SELPs are block copolymers that consist of repeating 
amino acid sequence blocks modeled from silkworm silk fibroin (GAGAGS) and 
mammalian elastin (GVGVP).(1) Depending on their specific sequence and composition, 
which can be precisely controlled, SELPs are soluble in aqueous solution at room 
temperature, can be mixed with viral gene carriers, and injected intratumorally where 
they form insoluble hydrogels for localized delivery. These polymers are produced using 
recombinant DNA technology, which allows for a high degree of control over both the 
sequence and length of the polymers formed. This class of polymers has undergone 
extensive characterization and analysis for their physicochemical properties and release 
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 characteristics cited elsewhere. (2-8) Our investigations of the structure-function 
relationship of SELPs enabled us to design SELP815K (Figure 3.1) to provide prolonged 
release of adenoviral vectors in a head and neck tumor model.(9, 10)  
However, SELPs present several challenges as biomaterials. SELPs have no prior 
history of FDA approved medical use, their biosynthesis is complex, and their 
manufacture can be costly. The question arises as to whether a readily available and FDA 
approved copolymer with appropriate injectability such as a Poloxomer can provide 
comparable performance to SELPs in intratumoral controlled release of adenoviruses. 
Poloxamers are triblock copolymers that consist of repeats of poly(oxyethylene) and 
poly(oxypropylene). These polymers have been studied and largely characterized in the 
controlled release and pharmaceutical industries.(11) Previous studies have shown that 
matrix-mediated delivery by these copolymers prolongs and localizes viral gene 
expression in vivo. In particular, Wang et al. studied this class of polymers with respect to 
localized adenoviral administration finding poloxamer 407 at a concentration of 21 wt. % 
to be the most effective formulation.(12) The studies in this chapter were designed to 
compare directly the in vivo safety and efficacy of these two biomaterials for matrix-
mediated viral gene delivery. 
 
3.2 Materials and methods 
3.2.1 Materials 
SELP815K was synthesized and characterized as previously described (structure in 
Figure 3.1A).(3) Poloxamer 407 (Figure 3.1B) was obtained from Sigma-Aldrich (St. 











Figure 3.1: Structure of investigated polymers: (A) silk, elastin, and lysine substituted 
elastin blocks in addition to SELP-815K in single amino acid code, (B) chemical 







adenovirus, containing E1 and E3 deletions, and the genes for thymidine kinase and 
firefly luciferase (Ad.Luc.HSVtk) were obtained from Vector Biolabs (Philadelphia, PA). 
The JHU-022 human oral cancer cell line was a gift from Prof. David Sidransky of Johns 
Hopkins University. Luciferin was obtained from Gold Biotech (St. Louis, MO), and 
bioluminesence was measured using a Xenogen IVIS100 bioluminescence imaging 
system from Caliper Life Sciences (Hopkinton, MA). Roswell Park Memorial Institute 
Advanced 1640 medium (RPMI 1640 Advanced), 100 mM L-glutamine, and TrypLE 
trypsin-like enzyme were obtained from Invitrogen (Carlsbad, CA). Fetal bovine serum 
was purchased from HyClone (Logan, UT). Sodium heparin was obtained from APP 
Pharmaceuticals (Schaumburg, IL). The prodrug ganciclovir (GCV) was purchased from 
Sigma-Aldrich (St.Louis, MO), athymic nu/nu mice and CD-1 mice (both female, 6 
weeks old) were obtained from Charles River Laboratories (Wilmington, MA ). Blood 
analysis was conducted using a HESKA Complete Blood Count Analyzer and HESKA 
DriCHEM 4000, HESKA (Loveland, CO). 
 
3.2.2 Study designs 
3.2.2.1 Squamous cell carcinoma model 
JHU-022 was thawed from frozen stocks of passage number less than 26 and 
expanded in culture for 2 weeks in RPMI 1640 Advanced medium from one T-75 culture 
flask to approximately 12 T-500 triple flasks. Cells were harvested from flasks by 
treatment with Tryple Express trypsin-like enzyme. Tryple Express was removed by 
centrifugation of the cells at 1000xg for 5 min and aspiration of the medium. Cells were 





mL. Tumors were induced in female athymic nu/nu mice by injecting 2.5 million cells 
(200µL) into the right flank of each animal and were allowed to grow for 10 days until 
they were 5mm to 7mm in largest dimension. 
Following tumor induction, 36 mice were randomly assigned to four treatment groups 
(9 animals per group): control (saline injection), virus only injection, poloxamer 407 + 
virus, and SELP815K + virus. Animals of each group except control were injected with 
5x10
8
 plaque forming units (pfu) of Ad.Luc.HSVtk suspended in a consistent volume of 
25µL. Control animals were injected with 25µL of 0.9% saline. The 25µL injection sizes 
have been determined as optimal from past lab experience of injection volumes for 
xenograft, head and neck mouse tumor models.(10, 13). The SELP815K + virus injection 
solution was prepared by thawing 12 wt% stock polymer solution stored in -80° C, 
mixing with the virus stock solution, and diluting with 0.9% saline to a final polymer 
concentration of 4% (w/v). The poloxamer 407 + virus injection solution was prepared by 
dissolving 0.21g dry poloxamer 407 to a final volume of 1.0 mL with fluid comprised of 
0.9% saline and virus stock solution to yield a final poloxamer 407 concentration of 21% 
(w/v). This concentration was chosen appropriate for release of viral carriers as 
determined by previous work. (12) Solvation of dry poloxamer 407 was achieved with 
repeated steps of ice chilling and vortexing.  Virus or control injections were 
administered to each animal after solid tumor formation. The time of virus injection was 
designated as day 0 of the study.  
Ganciclovir injection solution was prepared by dissolving the drug in 0.9% saline to a 
concentration of 1mg/mL. The drug was administered daily at a dose of 25mg/kg for the 





point was chosen due to pilot study data that suggested intratumoral expression of the 
therapeutic enzyme would be too low to warrant additional prodrug treatment after this 
time. Tumor size was measured using calipers biweekly for 50 days. All measurements 
were by the same investigator. Body weight was measured daily. Animals were observed 
daily for mortality and signs of tumor or treatment morbidity. There was no premature 
mortality in the study. By protocol, any animal that displayed tumor volume >2000 mm
3
, 
necrosis of tumor site, or greater than 10% weight loss was euthanized. Euthanasia was 
performed by CO2 asphyxiation. Final tumor size and body weight were recorded prior to 
euthanasia. The study protocol was approved and the study conducted under the authority 
of the Institutional Animal Care and Use Committee of the University of Utah. 
 
3.2.2.2 Intratumoral bioluminesence expression 
Cell culture, tumor induction, material preparation and administration, and treatment 
were performed as described in Section 3.2.2.1. Bioluminesence was generated in vivo by 
intraperitoneal injection of 200µL luciferin at a concentration of 15mg/mL in 0.9% 
saline. Imaging was performed 30 min after administration of luciferin to each mouse 
using a 30 second exposure time in a Xenogen IVIS 100 Imager. Images were analyzed 
using Igor Pro software from Caliper Life Sciences. Bioluminesence images were taken 
biweekly for 21 days. Animal body weight was monitored daily. Total photon count 
density for each animal tumor was determined using Igor Pro image analysis software 
provided by Caliper Life Sciences working in conjunction with the IVIS 100 imaging 
system. This software is capable of yielding photon count numbers for any region of 





by the authors in this case is an area of approximate size to each tumor while 
encompassing all photon emissions from each tumor. Total photon counts for all animals 
in each group will be averaged to yield the average total photon count for each study 
group. The study protocol was approved and the study conducted under the authority of 
the Institutional Animal Care and Use Committee of the University of Utah. 
 
3.2.2.3 Safety study 
Female CD-1 mice were randomly assigned to four treatment groups (40 animals per 
group): control (saline), virus only injection, poloxamer 407 + virus, and SELP815K + 
virus. Within each treatment group, animals were assigned to four sacrifice time points 
(10 per time point): 1 week, 2 weeks, 4 weeks, and 12 weeks. Animals of each group 
except control were injected with 3.79x10
9
 plaque forming units (pfu) of Ad.Luc.HSVtk 
suspended in each polymer or 0.9% saline. Material preparations for injections and 
treatment were performed in the same manner as described in Section 3.2.2.1 except that 
the injections on day 1 were administered subcutaneously and the volumes were 
increased to 50uL for each mouse in order to accommodate the increased viral dose. 
Each mouse was weighed and inspected daily during the treatment phase of the study 
(through day 28), then weekly for the remainder of 12 weeks. At the conclusion of each 
time point, designated mice were euthanized by CO2 asphyxiation and blood was 
immediately collected using 1.0 cc tuberculin syringes and 25G needles that had been 
previously flushed with 1000 IU/mL of sodium heparin to prevent coagulation. The heart, 
liver, lung, spleen, kidney, and the injection site of each animal were harvested and stored 





conducted under the authority of the Institutional Animal Care and Use Committee of the 
University of Utah. 
 
3.2.3 Analysis 
3.2.3.1 Blood analysis 
For complete blood counts, 20uL samples of heparinized, fresh, whole blood were 
drawn from each animal and analyzed within 1 hour of collection. Blood counts were 
performed using a Heska CBC Diff blood analyzer. Blood count parameters measured 
were total white blood cell count, lymphocyte count, monocyte count, granulocyte count, 
hematocrit, red blood cell count, mean corpuscular volume, red blood cell distribution 
width, hemoglobin concentration, mean corpuscular hemoglobin concentration, mean 
corpuscular hemoglobin, platelet count, and mean platelet volume.(14) For blood 
chemistry analysis, blood samples were centrifuged in heparinized vials at 10,000 RPM 
for 2 min and the plasma was analyzed for blood urea nitrogen, creatinine, total protein, 
albumin, total bilirubin, alanine aminotransferase, and aspartate aminotransferase.(15) 
Blood chemistry was performed using a Heska Dri Chem 4000 blood analyzer.  Normal 
ranges were used as defined from the blood analyzer manufacturer. 
 
3.2.3.2 Histology 
Animal tissue samples and organs were stored in 10% formalin for a minimum of 24 
hours to achieve fixation. Organs were further sectioned into slices approximately 2mm 
thick and embedded in paraffin. Subcutaneous injection sites including the surrounding 





sectioned by microtome to 5µm thick sections, mounted on glass slides, and stained with 
hematoxylin and eosin. Tissue and histological slide preparation was conducted by 
ARUP Laboratories (Salt Lake City, Utah). Slides were examined microscopically. 
 
3.2.3.3 Statistical analysis 
Student’s t-test was used to compute statistical significance between the treatment 
and control groups within studies. Mantel-Cox test was used for analysis of survival 
curves. A value of p ≤ 0.05 was considered statistically significant and p ≤ 0.01 was 
considered highly statistically significant. 
 
3.3 Results 
3.3.1 Efficacy in squamous cell carcinoma model 
The tumor model of head and neck squamous cell carcinoma (HNSCC) in mice was 
used to compare the performance of SELP815K and poloxamer 407 as matrices for viral 
gene delivery. This model was chosen for its ease of access to a tumor for local injection 
and treatment assessment, and because of the presence of the Coxsackievirus and 
adenovirus receptor (CAR) making them sensitive to adenoviral transfection.(16) 
Immune compromised athymic nu/nu mice were subcutaneously inoculated with the 
JHU-022 human HNSCC cell line isolated from a solid tumor of oral origin at Johns 
Hopkins University in the laboratory of Prof. David Sidransky.(17) Induced 
subcutaneously, these tumors grow rapidly to assess treatment benefits in a relatively 
short time period while avoiding the much greater mortality and morbidity of orthotopic 





Gene directed enzyme prodrug therapy (GDEPT) was the treatment modality used in 
this study. GDEPT relies on delivery of a gene for a therapeutic enzyme to targeted cells. 
The encoded enzyme converts a nontoxic, systemically administered prodrug into a 
cytotoxic metabolite that causes cell death only in transfected cells.(19) In this case, 
adenovirus containing the genes for thymidine kinase and luciferase was injected 
intratumorally at day 0 followed by daily systemic dosing of the nontoxic prodrug 
ganciclovir for the next 28 days. Transfected cells expressing thymidine kinase convert 
ganciclovir to ganciclovir phosphate, a cytotoxic metabolite. A limitation of this 
approach is the rapid dissemination of adenovirus from the site of injection, thus reducing 
the amount of local transfection and causing undesired systemic side effects. A matrix-
mediated approach is designed to control the release rate of virus over several weeks, 
limiting dissemination of virus from the injection site and increasing transfection in 
targeted local tissues over a longer period of time. While it has not been proven that there 
is a virus stabilizing effect of protein based SELP gels, it is hypothesized that the 
extended time frame of viral encoded protein presence in tumor cells compared to free 
viral injection previously seen could be due to an extended time of virus viability caused 
by protein-protein interactions within the SELP hydrogels, or by physical sequestration 
and protection of the viruses from the local environment.(10, 13) 
We used this tumor model and treatment strategy to compare the performance of the 
polymers SELP815K and poloxamer 407 in matrix-mediated viral gene delivery. On day 
1 of the study, mice with a tumor between 5-7 mm in longest diameter were injected 
intratumorally with 5x10
8
 plaque forming units (pfu) of Ad.Luc.HSVtk. The virus was 





based on our previous work(9) or poloxamer 407 (21% w/v concentration chosen based 
on published work).(12)  Control mice were injected with 0.9% saline. Ganciclovir was 
administered daily thereafter for 28 days to all groups including control. Animals were 
observed for 22 additional days posttreatment for a total study duration of 50 days 
(Figure 3.2A). As a stand-alone therapy, this treatment protocol is not intended to achieve 
tumor elimination in mice. The tumor size reduction followed by tumor rebound expected 
with this protocol provides a baseline for assessing the effectiveness of treatment options 
and variables.  
All virus treatment groups achieved greater reduction in mean tumor size than 
control, indicating that the virus was therapeutically active and that injection of the virus 
in SELP815K or poloxamer 407 did not abolish its therapeutic activity. Throughout the 
study, the SELP815K + virus group had the least mean tumor size of all treatment 
groups. The poloxamer 407 + virus group had the greatest mean tumor size of all 
treatment groups at all time points except days 47 and 50, when the virus only group was 
greater. However, at these last time points a greater number of animals in the poloxamer 
407 + virus group were eliminated by sacrifice due to excessive tumor morbidity. The 
differences in mean tumor size of the SELP815K + virus and the poloxamer 407 + virus 
groups were statistically significant from day 8 to day 36 and at day 43. Neither polymer 
treatment group achieved statistical significance from the virus only group.  
Tumor rebound, defined as the time after treatment that the mean tumor size of a 
group regained its day 0 average volume, demonstrated a similar difference between 
treatment groups. The first group to rebound was poloxamer 407 + virus at day 5. 














Figure 3.2: Effect of matrix mediated gene directed enzyme prodrug therapy on induced 
JHU-022 squamous cell carcinoma tumors in athymic nu/nu mice. (A) Left panel: tumor 
size measured with calipers biweekly and normalized to day 0; Right panel: larger view 
of treatment groups alone. (B) Survivability observed as number of animals not having: 
tumor volume exceed 2000mm
3
, unacceptable necrosis, or weight loss of >10%, 








+ virus group at day 36. 
The second outcome assessment of the efficacy study was survivability. Survival 
endpoint was defined by protocol as unscheduled mortality or sacrifice due to a tumor 
burden >2000mm
3
, an unacceptable level of tumor necrosis, or an unacceptable level of 
weight loss (>10%). The SELP815K + virus group did not have any unscheduled animal 
deaths for the duration of the study (100% survivability) while control and other 
treatment groups had multiple unscheduled sacrifices (Figure 3.2B). The poloxamer 407 
+ virus group and the virus only group had a final survivability of 33% and 56%, 
respectively. Statistical analysis using the Mantel-Cox test revealed that the SELP815K + 
virus treatment group had a highly statistically significant difference in survivability 
compared to poloxamer 407 + virus (p=0.0051) and was also statistically significant over 
virus only injection (p=0.038). 
 
3.3.2 Intratumoral expression 
To compare the release profiles of the matrix-mediated delivery systems in vivo, the 
intratumoral expression of viruses was analyzed as a function of bioluminescence 
produced by luciferase expression caused by transfection of released adenoviruses. This 
study was performed in the same mouse tumor model as the efficacy study using the 
same viral injection compositions and treatments (Section 3.1). At early time points, the 
virus only and SELP815K + virus treatment groups had indistinguishable average 
expression levels, however, the poloxamer 407 + virus group had a statistically 
significantly lower expression than the SELP815K + virus group at day 4 (Figure 3.3).  














Figure 3.3: Measured intratumoral bioluminescence from matrix delivered luciferase 
encoding adenovirus to JHU-022 squamous cell carcinoma tumors in athymic nu/nu 
mice. Bioluminescence measured biweekly and reported as average total photon count 
emitted from tumors during recording period. *SELP815K statistically significant from 









total expression level than the virus alone and the poloxamer 407 + virus groups. The 
poloxamer 407 + virus group did have higher tumor expression over virus alone from day 
14 to day 21. While bioluminescence is semiquantitative, these data were compared to 
quantitative beta-galactosidase expression from a separate adenoviral carrier in a separate 
study over similar time points and the trends were found to be similar (data not shown). 
 
3.3.3 Safety 
An important parameter for a matrix-mediated gene delivery approach is its safety. 
The possible effects on safety of SELP815K and poloxamer 407 viral injection on 
GDEPT treatment were evaluated. In this study, immunologically competent, nontumor 
bearing mice were used in order to include possible host-related immunological effects. 
Treatments and control were administered as in the efficacy and expression studies, 
except that a greater dosage of adenovirus was injected subcutaneously (3.79x10
9
 pfu of 
Ad.Luc.HSVtk per mouse) in a greater injection volume (50µL) to accommodate the 
larger viral dose. Animals were administered ganciclovir for 28 days, followed by a post-
treatment observation period through the 12-week endpoint of the study.  
Animal body weight was used as an indicator of overall animal health. As observed in 
Figure 3.4, no treatment group had a net mean body weight loss for the duration of the 
treatment. There were, however, statistically significant differences in mean body weight 
between all treatment groups compared to control from day 7 to day 28 (during the 
treatment period with ganciclovir). Immediately after day 28, the mean body weight of 
the SELP815K + virus treatment group recovered to nonsignificance compared to 












Figure 3.4: Effect of matrix mediated controlled release of therapeutic adenovirus to 
immune competent, nontumor bearing CD-1 mice. Animal weight as measured daily and 
normalized for percent weight change from day 0. †All treatment groups statistically 
significant from the control. ‡poloxamer 407 statistically significant from the control; 
*SELP815K statistically significant from the control; #Virus statistically significant from 









statistically significantly less than the control for the remainder of the study. The virus 
only group had a statistically significant difference in mean body weight from the control 
for approximately half of the posttreatment observation period.  
At the 1, 2, 4, and 12 week time points, 10 predesignated animals per group were 
euthanized and blood analysis was performed. All parameters measured in complete 
blood count and blood chemistry analyses (Section 2.3.1) yielded values similar to the 
control group except for white blood cell counts and total bilirubin. Individual values for 
total white blood cell counts at weeks 1 and 2 and total bilirubin at week 2 are shown in 
Figure 3.5. At week 1, an elevation in total white blood cell counts above the normal 
range was observed in 20%, 30%, and 40% of animals in the virus only, SELP815K + 
virus, and poloxamer 407 + virus treatment groups, respectively. At week 2, the percent 
of animals above the normal WBC range remained at 40% for the poloxamer 407 + virus 
group while it fell to 10% and none in the SELP815K + virus and virus only groups, 
respectively. At time points thereafter, WBC counts for all groups were within the normal 
range. The percent of animals with total bilirubin values outside the normal range was 
20% in the poloxamer 407 + virus group and none in the SELP815K + virus and virus 
only groups. No other abnormal blood count or blood chemistry values were obtained in 
the study.  
Microscopic examination of histological tissue sections obtained from the animals of 
all treatment groups and at all sacrifice time points showed no abnormalities or signs of 









Figure 3.5: : Effect of matrix mediated controlled release of therapeutic adenovirus to 
immune competent, nontumor bearing CD-1 mice on blood parameters as measured at 
necropsy. (A) week 1 total white blood cell count, (B) week 2 total white blood cell 
count, (C) week 2 total bilirubin. Normal ranges defined from blood analyzer 







3.3.4 Injection site histological evaluation 
Injection site tissues of animals in the safety study were prepared histologically and 
examined microscopically after staining with hematoxylin and eosin. Photomicrographs 
of representative injection site tissues at weeks 1, 2, 4, and 12 after injection are 
presented in Figure 3.6. The injection sites of animals administered virus in all groups 
displayed a subcutaneous lesion characterized by a granulomatous cellular infiltration as 
confirmed by ARUP Labratories. For animals of the SELP815K + virus group, the 
lesions were localized to an amorphous mass presumed to be the SELP815K polymer 
hydrogel. In the virus only and poloxamer 407 + virus groups, the lesions were more 
diffuse with multiple lesion locations. At week 1, the cellular infiltrate of injection sites 
of all virus injection groups was composed primarily of mononuclear leukocytes 
including neutrophils, monocytes, macrophages, and lymphocytes. At later time points, 
fibroblasts and occasional foreign body giant cells were observed. A notable difference 
between the treatment groups was the presence of adjacent tissue necrosis observed in the 
virus only and poloxamer 407 + virus groups, which was absent in the SELP815K + virus 
group. At week 1 and 2, tissue necrosis characterized by acellular prefibrotic tracts within 
the injection site was noted in the virus only injection group. These were not observed in 
the poloxamer 407 + virus or SELP815K + virus groups. Primarily at the early time 
points (Weeks 1 to 4), cellular necrosis of adipocytes was observed in the virus only and 
poloxamer 407 + virus group. Additionally, evidence of neural degeneration was 
observed in the poloxamer 407 + virus group. This was generally absent in the 
SELP815K + virus group. By week 12 the signs of injection were largely absent in all 















Figure 3.6: Effect of matrix mediated controlled release of adenovirus on injection site 
structure visualized via H&E stained injection sites from weeks 1, 2, 4, and 12 (left to 
right) and groups control, virus only, SELP815K + virus, and poloxamer 407 + virus (top 
to bottom). Normal fibrosis (green outline) due to injection is seen in control animals 
while necrotic tracts (red outline) and adipocytic necrosis (orange outline) can be seen in 
the virus only at weeks 1 and 2. Adipocytic necrosis is also seen in weeks 1, 2, and 4 in 
the poloxamer 407 + virus. Progressive encapsulation (purple outline) is seen in 










Consistent with previous work, our results demonstrate that gene-directed enzyme 
prodrug therapy (GDEPT) using an adenoviral vector is effective in reducing tumor size 
and increasing survivability in a mouse tumor model of HNSCC. Moreover, the efficacy 
and the safety of the treatment are improved using SELP815K for matrix-mediated 
localized delivery of the virus. The current studies compare SELP815K, a silk-elastinlike 
protein copolymer, with poloxamer 407, a commercially available synthetic copolymer, 
in their effectiveness and safety of administration of GDEPT.  
The results of the efficacy study indicated that GDEPT was more effective when 
virus was administered in SELP815K. The SELP815K + virus group had greater tumor 
size reduction and longer time until tumor rebound than the poloxamer 407 + virus and 
the virus only groups (Figure 3.2A). Survivability of the SELP815K + virus group was 
greater than for the poloxamer 407 + virus and the virus only groups (Figure 3.2B).  
We hypothesize that the increased effectiveness of GDEPT when administered in 
SELP815K is linked to increased levels and/or greater duration of expression of the viral 
genes. Indeed, the intratumoral expression analysis revealed that administration of virus 
in SELP815K produced early high-level viral gene expression comparable to virus only 
and maintained the highest levels of the three groups after day 14, when virus only levels 
were considerably reduced. Administration of virus in poloxamer 407, by contrast, 





somewhat maintained after day 14, greater than the virus only level over this period.  
The greater intratumoral expression of viral genes in the SELP815K + virus and the 
virus only groups correlated with the observed greater early reduction in tumor size 
compared to the poloxamer 407 + virus group. Additionally, the higher-level expression 
of viral genes in the SELP815K + virus group through day 21 correlated with the longest 
tumor rebound time (day 36) as compared to day 19 for the virus only and day 5 for the 
poloxamer + virus groups. It can also be seen that there may have been lingering efficacy 
post-day 28 when ganciclovir administration was discontinued. This could have been due 
to the half-life of the active metabolic product of ganciclovir being in cells12-18 hours, 
allowing for cytotoxic effects for some time after cessation of administration.(20) 
Additionally, tumor rebound was defined as the time after treatment that the mean tumor 
size of a group regained its day 0 average volume, and could have also contributed to the 
apparent lingering efficacy due to the time required for treated tumors to return to their 
initially measured size. These correlations are consistent with the presumption that high 
initial expression of the therapeutic gene is necessary for initial tumor reduction. When 
high initial expression was not present, as in the poloxamer 407 + virus group, the 
effectiveness of treatment decreased. Secondly, prolonged expression of the therapeutic 
gene prevented or delayed tumor rebound or recurrence. Even though the expression of 
the poloxamer 407 + virus group was sustained from day 14 to day 21 at a level greater 
than the virus only group, it apparently was not at a sufficient level to delay tumor 
rebound.  
A possible explanation could be the inherent release characteristics of a poloxamer 





small molecular weight drug release from poloxamer gels is dissolution of the matrix, not 
diffusion through the matrix.(11) The large size of adenovirus would likely entrap viral 
particles in the poloxamer gel limiting initial release at early time points, preventing high 
transfection and expression levels. Indeed, histological examination of the poloxamer 407 
+ virus injection sites revealed an absence of injected material after week 1, consistent 
with the rapid loss of the matrix.  
 Our safety study demonstrated no significant adverse effects related to the 
injection of virus in SELP815K or poloxamer 407. Even at a viral dose nearly 8 times 
that used in the efficacy and intratumoral expression studies, no treatment group showed 
signs of systemic toxicity indicated by significant loss of weight (Figure 3.4). This is a 
promising result as systemic immune reactions manifested as weight gain retardation and 
significantly elevated white blood cell populations to adenoviral administration have been 
observed previously in our studies using higher viral doses in nonmatrix mediated 
administration.(21)  Histological examination of heart, liver, lung, spleen, and kidney did 
not reveal any signs of pathology or abnormal anatomy. At early time points, elevated 
total white blood cell counts were observed as expected in response to adenoviral 
administration. Virus injected in SELP815K did reduce the number of animals with an 
elevated total white blood cell count in comparison with the poloxamer 407 + virus group 
at Week 2. Elevated total bilirubin levels at Week 2 were observed in the poloxamer 407 
+ virus group. However, the absence of elevated ALT and AST liver enzyme levels 
indicated that significant liver toxicity was unlikely.  
Examination of injection site histology revealed signs of localized inflammation and 





animals injected with virus only. The effects could result simply from the injection of a 
large titer of free adenovirus. Gross tissue necrosis was only observed in the virus only 
group, lending support to this hypothesis. Adipocytic necrosis was observed more 
broadly in both the virus only and poloxamer 407 + virus injection sites. This observation 
also persisted longer in the poloxamer 407 + virus group. While the effect was likely 
virus related, it also could have been exacerbated by poloxamer 407, which has been 
reported to have an adjuvant effect when administered with an immunological agent.(22) 
In fact, SELP815K + virus injection, which produced high early viral gene expression 
and tumor growth suppression, had a substantially reduced incidence of adipocytic 
necrosis indicating that the effect is not obligatorily associated with high early viral 
release. 
SELP815K hydrogel material was observed in the SELP815K + virus injection sites 
throughout the 12-week study. In contrast, virus only and poloxamer 407 + virus had no 
observable material present in the injection site tissues beyond 1 week. Over time, a 
fibrotic layer formed around the remaining gel mass eventually maturing to a compact, 
likely collagenous layer by week 12. Encapsulation appeared to occur after viral release 
and therapeutic activity was completed at day 28 (the treatment period) of the efficacy 
study, and therefore had no apparent effect on viral release from SELP815K. Beyond this 
point any effects on viral release of encapsulation would not be observed. 
Together, our results confirm the utility of SELP815K for matrix-mediated gene 
delivery. Compared to poloxamer 407, a commercially available synthetic copolymer, 
SELP815K had greater efficacy in tumor suppression, promoted greater levels and 





toxicity. Additionally, SELP815K displayed a comparable or better safety profile than 
poloxamer 407. With immunoreactivity among the chief concerns over the therapeutic 
administration of adenoviruses, it is noteworthy that SELP815K + virus injection resulted 
in less animals with elevated white blood cell counts and an absence of local toxicity 
reaction than was observed with poloxamer 407. SELP815K did, however, display 
encapsulation after injection in the subcutaneous tissue, likely due to its longer-term in 
vivo durability. Combining performance and safety with the degree of control with which 
they can be designed, synthesized and formulated, SELPs continue to show promise for 
their application in localized gene delivery. 
 
3.5 Conclusions 
SELP815K mediated viral GDEPT for treatment of HNSCC in a mouse tumor model 
showed the greatest average tumor size reduction, longest time to tumor rebound, and 
greatest survivability compared to virus only and virus administered in poloxamer 407. 
Its highest initial intratumoral expression of viral genes coupled with the increased 
duration of expression proved SELP815K superior to poloxamer 407 as a viral delivery 
matrix in this model. A safety assessment of local and systemic effects also demonstrated 
SELP815K comparable or superior to poloxamer 407 in moderating or avoiding possible 
immunological and local toxicity effects of adenoviral administration.  Consistent with 
previous reports, our findings indicate that poloxamer 407 may exacerbate some of these 
effects. Although it did not affect its therapeutic efficacy, SELP815K injection did result 
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EFFECT OF SHEAR ON PHYSIOCHEMICAL PROPERTIES OF  




Silk-elastinlike protein polymers (SELPs) are block copolymers consisting of 
repeating amino acid sequences modeled from silkworm silk fibroin (GAGAGS) and 
mammalian elastin (GVGVP) synthesized using recombinant DNA technology.(1) 
SELPs possess the unique property of transitioning from an aqueous solution into a 
physical network triggered by increase in temperature and dictated by the specific 
sequence and ratio of silk to elastin blocks. SELPs are liquid at room temperature to 
facilitate mixing with bioactive agents. When raised to body temperature they form 
insoluble hydrogels suitable for controlled release. The use of recombinant DNA 
technology in synthesis allows for a high degree of control over the sequence and length 
of the polymers formed, as well as the amino acid sequence-level precision at which 
modifications can be made to existing polymers.(2-7) SELPs have undergone extensive  
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characterization of physicochemical and release properties.(8-14) In the context of 
intratumoral gene delivery, it has been demonstrated that one particular analog of SELPs, 
namely SELP815K (Figure 1.2), holds promise for localized release of adenoviruses in 
the treatment of head and neck solid tumors.(15, 16) 
While SELPs, including SELP815K, have shown potential for use as controlled 
release matrices, their observed in vivo durability as biomaterials in murine models leads 
to progressive encapsulation over 12 weeks as demonstrated in the previous chapter.(17) 
In order to promote more rapid degradation, a SELP analog with sequences degradable 
by matrix metalloproteinases (MMPs) was synthesized.(18) It was demonstrated that 
these hydrogels degrade in the presence of MMPs, a family of naturally occurring 
proteases that function to breakdown extracellular matrix proteins that are over expressed 
in a variety of solid tumors.(19) The influence that the location of MMP responsive 
sequences in the SELP backbone may have on physicochemical properties of the 
resulting hydrogels and release characteristics from these matrices is, however, unknown. 
In this chapter several analogues of SELPS were biosynthesized by inserting the MMP 
responsive sequences into two structurally distinct regions of each monomer repeat, 
namely the silk block and the elastin block (Figure 1.2). Following synthesis and initial 
experiments on the physiochemical properties of new analogues, it was determined that 
mechanical conditioning of the synthesized material could be used for normalization of 
properties and to obtain a more robust polymer network. 
Shear stress has long been postulated to contribute to protein denaturation and has 
been shown to be utilized in living systems to affect conformational change in circulating 





via high fluid flow, particularly in molecules such as DNA whose conformation depends 
on weaker noncovalent bonds.(22) Applying mechanical shear stress to stable globular 
proteins, however, has shown to be less effective than expected in completely breaking 
secondary and tertiary conformational bonds due to the combination of weak interactions 
together with covalent bonds.(23) Proteins with weaker, less defined single strand tertiary 
structure such as SELPs may be more susceptible to the denaturing effects of shear stress. 
This will render linearized polymer strands that can form a higher density of 
intermolecular interactions. Here, we report the biosynthesis and characterization of new 
MMP responsive SELPs and the influence of high shear rate on the physiochemical 
properties of these polymers in the context of controlled release. 
 
4.2 Materials and methods 
4.2.1 Materials 
SELP815K(9) and SELP815K-RS2 with MMP responsive sequence in the middle of 
elastin blocks(18) were synthesized and characterized as previously described (Figure 
1.2). SELP815K-RS1 with a MMP responsive site located in the junction between silk 
and elastin blocks, and SELP815K-RS5 (RS5) with a MMP responsive sequence in the 
middle of silk blocks (Figure 1.2) were synthesized and characterized using the methods 
previously described for SELP815K-RS2.(18) All restriction enzymes, T4 ligase, and 
phosphatases were purchased from New England Biolabs (Ipswich, MA) or Fermentas 
(Vilnius, LT). C5 Emulsilex was purchased from Avestin (Ottawa, ON) and modified 
using high pressure valves and fittings from Autoclave Engineers (Erie, PA). 









4.2.2.1 SELP815K-RS5 synthesis 
SELP815K-RS1 and SELP815K-RS5 were synthesized and characterized using 
methods previously described for SELP815K-RS2.(18) Briefly, DNA oligomers 
encoding the MMP responsive amino acid sequence GPQGIFGQ were inserted into the 
SELP815K monomer in a construction plasmid using restriction endonucleases to 
linearize plasmid, and T4 DNA ligase to recircularize with responsive sequence inserted. 
The MMP responsive monomer population was then expanded and digested from the 
construction plasmid using BanI. The population of MMP-responsive monomers was 
multimerized by random concatemerization into a high efficiency expression plasmid 
using T4 DNA ligase and screened by size using XcmI, NcoI double digest run on a DNA 
agarose gel. Expression was confirmed using shake flask culture and SDS-PAGE protein 
gel. Protein was then expressed at 10L fermentation scale and purified from 1Kg wet cell 
pellet using several precipitation, ion exchange chromatography, and ultra filtration steps. 
The product was characterized via SDS-PAGE protein gel, matrix-assisted laser 
desorption/ionization time of flight (MALDI-ToF, University of California at Los 
Angeles proteomics core, Los Angeles, CA), and vapor phase hydrolysis amino acid 








Protein polymers were lyophilized and stored at -80° C following synthesis and 
purification. Lyophilized stocks were reconstituted completely in cold 0.7x PBS and kept 
on ice. Avestin C5 Emulsiflex homogenizer was washed thoroughly using depyrogenated 
deionized water and PBS. Homogenizer was then submerged in an ice bath to maintain 
low temperature during shear processing. Reconstituted protein polymer solution was 
pipetted aseptically into sample vessel and pressurized to 80 psi using nitrogen. The 
homogenizing valve was opened to allow a flow rate of approximately 5 mL/min and 
sample fluid was pumped through a needle valve at 17,000 psi. Material was then 
collected using a sterile luer connection. Sample fluid was aliquoted and snap frozen in 
liquid nitrogen. Frozen sheared polymers were stored at -80° C. 
 
4.2.2.4 Minimum gel forming concentration 
Minimum gel forming concentration was determined by qualitative observation of 
mechanical stability following extrusion from the barrel of a 1 mL tuberculin syringe 
with the tip removed. Frozen polymer samples were thawed in a room temperature water 
bath and diluted in PBS to concentrations with a 1% step from 0% wt/wt polymer to 15% 
wt/wt polymer. Resulting solutions were drawn into 1mL slip tip syringes and incubated 
overnight at 37°C. Syringe tips were then removed with an autoclaved razor blade and 
contents were extruded and sectioned into 50uL gel discs. Minimum gel forming 
concentration was defined as the concentration at which no lower concentration would 






4.2.2.5 Swelling ratio 
Swelling ratio was assayed on gel discs formed by extrusion from 1mL syringes in 
the same method as minimum gel forming concentration. Gel cylinders were extruded 
from syringe barrels and sectioned into 50uL discs using an autoclaved razor blade. 
Subsequently, discs were incubated in 500uL release media composed of 1x PBS + 
0.2mM sodium azide for 7 days to remove soluble fraction. Following incubation, gels 
were removed from release media, blotted dry with a lint free wipe, and weighed. Gels 
were then frozen and lyophilized for 3 days to remove water content and weighed again. 
Swelling ratio was calculated by dividing wet weight by dry weight.(24) 
 
4.2.2.6 Soluble fraction 
Soluble fraction was assayed using chromogenic modified Lowry assay and UV-vis 
spectrophotometer with standard curve consisting of serial dilution of SELP and MMP-
responsive SELP protein to determine the amount of protein in release media collected in 
the swelling ratio experiment. Soluble fraction was calculated by dividing soluble protein 
by soluble protein plus dry weight of respective hydrogel.(25) 
 
4.2.2.7 Nanoparticle release 
Model nanoparticle release was assayed using 50uL gel discs loaded with 110nm 
fluorescently labeled polystyrene spheres prepared in the same method as detailed above. 
Gel discs were incubated for 28 days in 500uL release media composed of 1x PBS + 
0.2mM azide. Release media was collected, gels were washed, and media replaced on 





by fluorescence quantification of FITC label after excitation at 260nm with emission at 
515nm. Fluorescence photo bleaching and degradation were accounted for with internal 
polystyrene bead control group.  
 
4.2.2.8 Rheological analysis 
Rheological analysis was performed using an AR 550 stress-controlled rheometer 
from TA Instruments (New Castle, DE) in a cone-and-plate configuration using a steel 20 
mm diameter, 4° cone. Oscillatory time sweeps were performed on each sample 
consisting of an equilibration time sweep at 23°C, angular frequency of 6.283 rad/s, and 
1.0 % strain for 1 min followed by a 5 hr sweep at 37°C, angular frequency of 6.283 
rad/s, and 0.1% strain. Briefly, individual polymer samples previously prepared to the 
correct concentration by dilution with 1x PBS and flash frozen were thawed just prior to 
assay in cool water and immediately transferred to the Peltier plate preheated to 23°C at a 
volume of 150µL. The equilibration step ended with a temperature ramp to 37°C in 30-60 
seconds before start of the 5hr run. The time sweep resulted in traces for G’ and G”, the 
storage and loss moduli, respectively. The G’ plateau represents dynamic gel strength, 
and was extracted for each sample at the 4hr time point. Due to the crystalline nature of 
the gelation, which in some cases caused cone detachment from the sample, several runs 
were unable to be completed to 5hrs; therefore 4hr point was chosen for consistency. 









4.2.3.1 Statistical analysis 
Student’s T-test was used to compute statistical significance between the two groups. 
One way ANOVA with Bonferroni posttest was used to compute statistical analysis of 
groups of three or more.  A value of p ≤ 0.05 was considered statistically significant and 
p ≤ 0.01 was considered highly statistically significant. All error bars displayed represent 
standard deviation of mean. 
 
4.3 Results 
4.3.1 Synthesis of SELPs 
SELP815K and SELP815K-RS2 were synthesized and purified as previously 
described(9, 18) and found to be identical to previous confirmed sequence batches by 
plasmid DNA sequencing, SDS-PAGE, mass spectrometry, and amino acid analysis. 
SELP815K-RS1 and SELP815K-RS5 were synthesized using similar strategy to 
SELP815K-RS2 and confirmed to be the correct size via plasmid DNA sequencing, gel 
electrophoresis, and mass spectroscopy (Figure 4.1). The predicted size of SELP815K-
RS1 is 69,443 DA, SELP815K-RS5 is 70,211 Da, and SELP815K is 64733. Mass 
spectroscopy found the sizes to be 69,298 Da, 69,142 Da, and 63,766, respectively. 
Amino acid analysis confirmed the presence of additional residues of the low occurrence 
amino acids isoleucine, phenylalanine, and glutamine in SELP815K-RS5 and 
SELP815K-RS1, as compared to the confirmed sequence of SELP815K corresponding to 












Figure 4.1: Characterization of SELP815K-RS5. (Bottom) matrix-assisted laser 
desorption/ionization time of flight (MALDI-ToF) mass spectrometry of SELP815K-
RS5 and SELP815K-RS1 with previously confirmed sequence SELP815K internal 
control, (Top). HCl vapor hydrolysis amino acid analysis of SELP815K-RS5 and 
SELP815K-RS1 with previously confirmed sequence SELP815K internal control. 
+
Amino acid additions characteristic of responsive sequence insertion. *Glutamine 
converted to glutamate (glx) by hydrolysis. **Quantification of these amino acids 
error prone by this method. 815K-SELP815K, RS1-SELP815K-RS1, RS5-
SELP815K-RS5. N=3. For structure of polymers see Figure 1.2. For mass spectra see 






(Figure 1.2).  
 
4.3.2 Minimum gel forming concentration 
Minimum gel forming concentration (MGFC) was determined as an initial indication 
of the change in mechanical properties exhibited by each polymer before and after 
shearing. Uniformly and repeatedly, shearing resulted in a lower MGFC. Native 
SELP815K showed the least change, decreasing its MGFC from 3% to 2% following 
shearing. SELP815K-RS5 showed the greatest change with shearing as the MGFC 
decreased over 3 fold from 13% to 4% while shearing of SELP815K-RS2 and 
SELP815K-RS1 resulted in medial decreases from 4% to 3% and 4% to 2%, respectively 
(Table 4.1). Results were repeated in triplicate. 
 
4.3.3 Swelling ratio 
The swelling ratio of each polymer was also assayed following the shearing. The 
change in swelling ratio was affected not only by the presence or absence of shear, but 
also the shear rate (Figure 4.2A). This can be observed in SELP815K, where lower shear 
pressure of 4,000 psi resulted in properties intermediate to unsheared and the maximum 
shearing pressure of 17,000 psi. Similar trends were observed for polymers SELP815K-
RS1 and SELP815K-RS2, as SELP815K where higher weight percent hydrogels resulted 
in a lower swelling ratio, and the greatest difference between sheared and unsheared 
manifested at the lowest weight percent tested (Figure 4.2B and Figure 4.2C). Testing 
between sheared and unsheared SELP815K-RS5 showed the least variability across 


















Table 4.1: Minimum gel forming concentration of 
SELP815K, SELP815K-RS1, SELP815K-RS2, and 
SELP815K-RS5 solvated in cold PBS and sheared at 
17,000 psi or without shearing. Polymers were allowed 
to gel for 24 hrs at 37 
0
C prior to extrusion from the 
barrel of 1 mL tuberculin syringes for qualitative 
analysis of ability to hold form after sectioning. 
Polymers were assayed at 1% wt/wt concentration 
increments. Concentrations shown are % w/w. For 







  Figure 4.2: Swelling ratio of (A) SELP815K, (B) SELP815K-RS1, (C) SELP815K-
RS2, and (D) SELP815K-RS5 calculated by wet weight/dry weight. (E) Comparison 
of swelling ratio of low concentration SELP815K-RS5 with SELP815K, SELP815K-
RS1, and SELP815K-RS2. NS-Not Sheared, PS-Partial Shear (4000psi), FS/S-(Full) 
Shear (17000psi). All percentages expressed as % wt/wt. N=4-5. For structure of 






types showed no significant difference between SELP815K, SELP815K-RS1, and  
SELP815K-RS2 at 10.7% wt/wt and 8% wt/wt, but SELP815K-RS5 showed a significant 
increase in swelling ratio compared to the other two polymers at gel forming 
concentrations (Figure 4.2E). The lowest concentration tested of SELP815K, SELP815K-
RS1, and SELP815K-RS2 of 4% wt/wt was not tested for SELP815K-RS5 due to its 
higher MGFC. In all polymers shearing decreased the measured swelling ratio. 
 
4.3.4. Soluble fraction 
The soluble fraction of SELP815K, SELP815K-RS1, and SELP815K-RS2 showed 
similar trends, and statistical significance was achieved between sheared and unsheared 
forms of the polymers at all concentrations tested (Figure 4.3). It was further observed 
that SELP815K-RS5 soluble fraction did not differ as highly between sheared and 
unsheared at the concentrations that enabled this comparison (Figure 4.3B). Additionally, 
SELP815K-RS5 showed the highest soluble fraction release of any polymer tested at 8% 
wt/wt or higher. SELP815K-RS5 showed greater than 25% soluble fraction release at 
10.7% wt/wt and 8% wt/wt while SELP815K, SELP815K-RS1,and SELP815K-RS2 
showed less than 13% soluble fraction release at 10.7% wt/wt and 8% wt/wt. SELP815K-




Rheological properties were compared after shearing for the polymers using a TA 
















Figure 4.3: Soluble fraction of (A) SELP815K, SELP815K-RS2, (B) SELP815K-
RS1, and SELP815K-RS5 assayed using chromogenic modified Lowry assay for 
protein content in release media of hydrogels after 7 days. Soluble fractions 
computed by weight soluble protein / (weight soluble protein + hydrogel dry weight 
at day 7). S-Sheared, NS-Not Sheared, 815-SELP815K, RS1-SELP815K-RS1, 
RS2- SELP815K-RS2, RS5-SELP815K-RS5 (sequences in Figure 1.2). N=4-5. 
(A)***-p ≤ 0.001 for SELP815K points, +++-p ≤ 0.001 for SELP815K-RS2 points, 
++-p ≤ 0.01 for SELP815K-RS2 points, (B) *-p ≤ 0.05 for SELP815K-RS5, ***-p 







was measured over 4 hours at 37°C for each polymer with and without shear (Figure 4.4). 
Sheared samples showed more rapid gel formation and higher modulus plateau for all 
polymers. Sheared samples also showed closer adherence to ideal stiffness curves with 
rapid initial increase in modulus without disruption followed by plateau and curing. The 
stiffness at 4 hours obtained for each polymer is compared in Figure 4.4E. The largest 
difference was observed in SELP815K-RS5, which was statistically significant when 
sheared and unsheared polymers at identical concentrations were compared. Sheared 
SELP815K-RS5 showed an over 2 fold increase in stiffness at 14 % wt/wt. Statistically 
significant increases in stiffness were also recorded for SELP815K-RS1 at 4% wt/wt and 
10.7% wt/wt. Increases in stiffness were also observed in SELP815K and SELP815K-
RS2, although these changes were not found to be statistically significant. 
 
4.3.6 Nanoparticle release 
Release of 110nm polystyrene beads showed the least change as a function of shear, 
although several trends were observed across polymer types and concentrations (Figure 
4.5). Unsheared hydrogels released more over 28 days than their sheared counterparts 
except in a single instance in which the two differed by less than one standard deviation. 
On average, SELP815K-RS5 released the highest amount over 28 days followed by 
SELP815K-RS2. SELP815K released the least on average although the differences in the 
three polymers were not statistically significant. SELP815K-RS1 showed the broadest 
range of release between sheared and unsheared polymers, which resulted in statistical 
significance being achieved. SELP815K, SELP815K-RS1, and SELP815K-RS2 












Figure 4.4: Rheological analysis performed on sheared and unsheared polymers. (A) 
SELP815K at 4% and 10.7% wt/wt polymer, respectively; (B) SELP815K-RS1 at 4% 
and 10.7% wt/wt, (C) SELP815K-RS2 at 4% and 10.7% wt/wt, and (D) SELP815K-
RS5 at 18%, 14%, and 10.7% wt/wt polymer, respectively. (E) Final gel stiffness at 
the end of 4 hour run at 37° C for each polymer and concentration. S-Sheared, NS-
Not Sheared, 815-SELP815K,RS1-SELP815K-RS1 RS2-SELP815K-RS2, RS5-
















Figure 4.5: Release of 110nm fluorescently labeled polystyrene beads from (A) 
SELP815K, (B) SELP815K-RS1, (C) SELP815K-RS2, and (D) SELP815K-RS5 over 
28 days from 50uL gels into 500uL of release media consisting of PBS + 0.2mM 
sodium azide. Release media was removed and gels were washed at each time point 
to simulate infinite sink conditions.  Graphs represent running total of fluorescence 
released assayed by UV-vis corrected for photo bleaching and degradation. S-
Sheared, NS-Not Sheared, 815-SELP815K, RS1-SELP815K-RS1, RS2- SELP815K-
RS2, RS5-SELP815K-RS5 (sequences in Figure 1.2). N=4. **-p ≤ 0.01, ***-p ≤ 







results with other SELPs.(10) SELP815K-RS5 deviated from the expected trend with low 
weight percentages releasing slower than high weight percentages. While this result was 




The physiochemical properties of protein based polymers can be manipulated by 
changing the amino acid sequence of the polymer backbone. Due to the exquisite control 
of recombinant DNA technology one is able to incorporate changes into polymer 
sequences precisely with near monodisperse precision. By measuring classical hydrogel 
properties such as swelling ratio and soluble fraction release along with the mechanical 
properties as exhibited by the MGFC and rheology, we were able to examine the 
structure-function relationship of each insertion into the polymer sequence. As these 
polymers are to be used as controlled release depots, it was also important to assay the 
change in temporal release caused by responsive sequence insertion. We predicted 
responsive sequence insertion into the silk domain of SELP815K would result in greater 
structure disruption than insertion into the elastin domain or the junction between silk and 
elastin units due to the nature of the silk domains to form structurally important beta-
sheets. Unexpected was the extent to which shear processing was able to rescue the 
mechanical stability lost by sequence disruption in SELP815K-RS5. 
Minimum gel forming concentration (MGFC) as an initial indicator of mechanical 
properties behaved as expected with respect to shear and polymer. We assumed the 





interactions from the polymers leading to less intramolecular interactions, and as a result 
allow for more intermolecular bond formation upon gel formation creating a robust 
polymer network. Data showed this hypothesis to be true as the application of shear 
lowered the MGFC across the board and mirrored the predicted mechanical structure 
disruption. SELP815K-RS5 with MMP-responsive sequences located in the main 
structural component of the polymer, the silk, would have the highest MGFC while the 
native SELP815K with no structural disruption to the silk or elastin units would have the 
lowest MGFC (Table 4.1). 
As with MGFC, the swelling ratios of tested polymers were uniformly affected by 
shear processing. Increased shear rate resulted in a marked decrease in swelling ratio 
(Figure 4.2). This was likely the result of greater intermolecular interaction due to the 
disruption of weak noncovalent intramolecular bonds by shear stress. Interestingly, the 
effect on swelling ratio is shear rate dependent with 4,000psi shear pressure having less 
effect on the polymer systems than 17,000psi. This indicates that the intramolecular 
interactions are of varying strength, requiring variable shear rate to disrupt these 
structures from the polymers (Figure 4.2A). Comparing between polymers, it is observed 
that SELP815K, SELP815K-RS1 and SELP815K-RS2 with the MMP-responsive 
sequence in the elastin blocks and in the junction between silk and elastin blocks do not 
differ significantly at higher concentrations. SELP815K-RS1 did show a statistical 
difference at the lowest concentration tested, 4% wt/wt. However, SELP815K-RS5 
shows significant difference from other polymers with a much higher swelling ratio at the 
same concentration likely due to the disruption of crystal structure normally formed by 





The soluble fractions released from hydrogels formed from each polymer were 
similarly affected by shearing. Across all polymers, hydrogels formed from unsheared 
polymers had significantly higher soluble fraction release compared to hydrogels formed 
from sheared polymers at the same concentration. Additionally, lower weight percent 
hydrogels had higher soluble fraction release compared to higher weight percent gels 
(Figure 4.3). This was expected as the likely higher percent of intramolecular interactions 
prior to shear allow for less intermolecular forces to hold polymer strands within the 
hydrogel network. It is also apparent that structural disruption of the polymer network 
plays a significant role in soluble fraction release as sheared SELP815K-RS5 showed 
significantly higher soluble fraction release than sheared SELP815K, SELP815K-RS1, or 
SELP815K-RS2 at the same concentrations. Additionally, despite high weight percent 
sheared formulations, SELP815K-RS5 was unable to retain more than 80% of initial 
polymer strands while SELP815K and SELP815K-RS2 were able to retain over 93%. 
SELP815K-RS1 was intermediate to these cases, retaining approximately 87% of 
polymer strands at 10.7% wt/wt. This result may indicate responsive sequence insertion 
adjacent to the silk block can cause some long range structural distruption. 
Gelation behavior of polymers tested using rheology gave further data supporting the 
hypothesis that shearing promotes more intermolecular interaction between polymer 
strands for a more robust gel network. This is illustrated in the increase in mechanical 
stiffness seen in all polymers after shearing (Figure 4.4). Furthermore, similar to 
observed MGFCs of each polymer, the polymer with the most disrupted structure, 
SELP815K-RS5, achieved the greatest increase in stiffness after shearing suggesting 





introduction of the responsive sequence (Figure 4.4E). As with soluble fraction release an 
intermediate but statistically significant increase in rigidity was also observed in 
SELP815K-RS1 indicating increased structural disruption by the location of the 
responsive sequence as compared to SELP815K and SELP815K-RS2. 
Release from SELP gels was expected to follow trends observed previously in other 
SELP polymers such as SELP415K and SELP47K with lower weight percent gels 
releasing particle load faster as a result of less cross-linking density and, by extension, a 
larger pore size.(10) Further, any parameter that increases cross-linking density and 
robustness of the network such as shearing should yield lower release rates. These trends 
were seen in SELP815K, SELP815K-RS1, and SELP815K-RS2. However, the reverse 
trend was observed in SELP815K-RS5 with lower weight percent gels releasing particle 
load slower in the sheared group (Figure 4.5). While interesting this result was not 
statistically significant and may be a result of study artifacts. In all release studies, ideal 
low burst release and linear character of release thereafter was observed. It is important to 
note that less than 1% of the particle load was released by all gels at day 28. This shows 
the release kinetics of this gel system will be ideal for delivery of drug containing 
nanoparticles based on degradation enzyme levels present in the injection site.  
From these results it is clear polymer sequence and structure have a direct impact on 
the resultant hydrogel physiochemical properties. By altering the insertion site of the 
MMP-responsive sequence we can see measurable changes in the swelling ratio, soluble 
fraction, and gelling behavior of each of the constructs. As predicted, the insert distance 
from the silk blocks was shown to be the primary determining factor in change of 





elastin blocks showed minor changes to hydrogel properties, while moving the insert 
adjacent to the silk blocks increased structural disruption, and insertion within the silk 
blocks led to dramatic increases in the swelling ratio and soluble fraction. This shows that 
the shift in hydrogel characteristics and mechanical properties in SELP185K-RS5 may 
exclude it from application as a controlled release matrix. Further analysis is needed to 
determine the effects of polymer sequence on the rate of degradation in vitro and in vivo. 
 
4.5 Conclusions 
Two new SELP analogs with MMP responsive sequences placed in silk units and the 
junction between silk and elastin units were synthesized. The application of shear stress 
to this and other SELP analogs with and without MMP responsive sequences resulted in 
quantifiable changes in physiochemical properties. These included influencing the 
minimum gel forming concentration, soluble fraction, swelling ratio, and mechanical 
stiffness. Further, shearing enables the use of polymer compositions with disruption in 
structurally important subunits by significantly lowering the concentration of polymer 
needed to form hydrogels. These findings have significant implications in the design of 
recombinant silk-elastinlike polymers for controlled delivery of bioactive agents where 
responsiveness to matrix metalloproteinases is desired. 
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IN VIVO EVALUATION OF MATRIX METALLOPROTEINASE RESPONSIVE 
SILK-ELASTINLIKE PROTEIN POLYMERS FOR 
CANCER GENE THERAPY 
 
5.1 Introduction 
Silk-elastinlike protein polymers (SELPs) are block copolymers composed of amino 
acid motifs inspired from nature in the form of silkworm silk fibroin (GAGAGS) and 
mammalian elastin (GVGVP) synthesized in E. coli using genetic engineering 
techniques.(1) Uniquely, SELPs are capable of a sol to gel transition in situ through an 
increase in temperature allowing for ex vivo loading of bioactive agents while 
maintaining an injectable formulation. The phase transition of these materials is dictated 
by the ratio and sequence of silk to elastin components. A high degree of control over the 
polymer sequence using recombinant DNA technology enables the engineering of 
specific phase transition behavior and physical properties.(2-7) Previously, SELPs have 
been extensively characterized for their physicochemical properties and release 
characteristics.(8-14) In the context of localized, matrix mediated gene delivery to solid 
tumors, it has been demonstrated that an analog of SELPs, namely SELP815K (Figure 
1.2), shows capability for localized release of adenoviruses.(15, 16)  
 
 





While SELP815K has shown impressive efficacy of adenoviral gene delivery and 
survival elongation in xenograft models, in vivo resistance to degradation has been 
observed due to fibrotic encapsulation when embedded for 12 weeks.(17) In order to 
promote absorption through more rapid degradation, SELP analogs with peptide 
sequences known to be readily cleaved by matrix metalloproteinases (MMPs) were 
synthesized.(18, 19) These insertions were made in both the silk and elastin blocks that 
represent structurally distinct regions of the polymer backbone and at the junction 
between these two blocks. By inserting the MMP-responsive sequence in each location, 
we were able to systematically evaluate the effect of the sequence on physiochemical 
properties as a function of insert location (Figure 1.2). A shear conditioning protocol was 
further developed to strip intramolecular secondary structures to allow for more long-
term interstrand interactions and robust hydrogel formation.(19)  
MMPs, a family of naturally occurring proteases that function to breakdown 
extracellular matrix proteins, were selected as the target enzyme due to their frequent 
over expression in a variety of solid tumors.(20, 21) The influence of the location of the 
MMP responsive site, GPQGIFGQ in single amino acid code, in the polymer backbone 
on physiochemical properties was investigated previously as the sequence is known to be 
cleaved with high efficiency by MMP-2 and MMP-9. It was shown that insertion of 
foreign sequences into the less structurally important elastin region and at the junction 
between the silk and elastin regions, termed SELP815K-RS2 and SELP815K-RS1, 
respectively, resulted in little observable structural disruption with only minor increases 
in swelling ratio, soluble fraction, and rheological properties. Insertion of foreign 





SELP815K-RS5, resulted in drastically increased swelling ratio, soluble fraction, 
minimum gel forming concentration, and poor rheological properties. As discussed in 
Chapter 4, only through physical conditioning with high shear stress was SELP815K-RS5 
capable of being used as a controlled release matrix at typical concentrations of 4-12% 
wt/wt.(19) In this chapter we build upon those findings to report the influence of polymer 
structure on in vitro degradation of the three MMP responsive SELP analogs (Figure 1.2), 
as well as on efficacy of matrix mediated viral gene delivery in a tumor xenograft model 
of head and neck squamous cell carcinoma (HNSCC).  
Building on previous work in our lab, an adenovirus carrying the herpes simplex 
thymidine kinase (HSVtk) and luciferase genes was chosen for gene-directed enzyme 
prodrug therapy (GDEPT) in the in vivo efficacy studies.(22) Briefly, viral infection of 
the HNSCC cells leads to expression of HSVtk, which phosphorylates the injected 
prodrug ganciclovir into ganciclovir phosphate, a potent DNA synthesis inhibitor acting 
through chain termination. Cell proliferation is inhibited, ultimately causing cell death 
and tumor regression. Luciferase expression allows for bioluminescent tracking of viral 
expression via light generated from interaction with luciferin. Controlled release of the 
viral particles used from GDEPT has previously shown to increase effectiveness of the 
treatment. In this chapter controlled release from the structurally related MMP responsive 









5.2 Materials and methods 
5.2.1 Materials 
SELP815K(9), SELP815K-RS2(18), SELP815K-RS1, and SELP815K-RS5(19) 
(Figure 1.2) were synthesized, purified and characterized as previously described. 
Materials for Lowry assay were purchased from Thermo Fisher Scientific (Waltham, 
MA). Matrix metalloproteinases were obtained from EMD Millipore (Billerica, MA). 
Replication deficient human adenovirus, containing E1 and E3 deletions, and the genes 
for thymidine kinase and firefly luciferase (Ad.Luc.HSVtk) were obtained from Vector 
Biolabs (Malvern, PA). Luciferin was obtained from Gold Biotechnology (St. Louis, 
MO). Six week old female athymic nu/nu mice were acquired from Charles River 
Laboratories (Wilmington, MA). JHU-022 human oral cancer cell line was a generous 
gift from Prof. David Sidransky of Johns Hopkins University. Live bioluminescence 
imaging was performed using a Xenogen IVIS100 system from Caliper Life Sciences 
(Hopkinton, MA). Roswell Park Memorial Institute Advanced 1640 medium (RPMI 1640 
Advanced) and supplements were purchased from Invitrogen (Carlsbad, CA). Fetal 
bovine serum was obtained from HyClone (Logan, UT). The prodrug Ganciclovir (GCV) 
and other general chemicals not listed by name were purchased from Sigma–Aldrich (St. 
Louis, MO). Tissue fixation, embedding, and histological staining were performed by 










5.2.2.1 Soluble polymer MMP digests 
Lyophilized stocks of each SELP analog were solubilized to a concentration of 
5mg/mL as a stock solution in deionized water. Each stock solution was formulated to a 
final concentration of 1mg/mL in MMP reaction buffer consisting of 50 mM Tris-HCl, 
150 mM NaCl, 5 mM CaCl2, and 40nM MMP-2. Reactions were incubated at room 
temperature (23° C) and samples were taken at 0, 10, 20, 30, 60, and 120 min. Samples 
were immediately mixed with SDS-PAGE sample buffer (Laemmli Buffer) and heated to 
95° C for 5 min to completely inactivate enzymes.(23) Samples were then loaded onto a 
20% acrylamide SDS-PAGE protein gel and run for approximately 2 hours. Gels were 
washed in deionized water, stained with Coomassie Brilliant Blue gel stain, and destained 
in 10:40:50 acetic acid:methanol:water. Stained gels were imaged in a UVP Bioimaging 
system. 
 
5.2.2.2 Hydrogel MMP digests 
Freshly thawed SELP stocks at 12% were diluted to 4%, 5%, or 8% wt/wt and loaded 
into 0.5mL syringes. Syringes were incubated overnight at 37° C to allow for complete 
gelation. Each syringe tip was removed with an autoclaved razor blade and 25uL gel 
disks were cut. Each 25uL disk was placed into a separate well of a 96 well plate in 
125uL of MMP reaction buffer of the above composition. Reaction buffer with MMP-2 
was completely removed and replaced every 36 hours for 14 days. Total soluble polymer 
released was assayed via modified Lowry assay and summed over the study period. 





dried by lyophilization over 3 days. 
 
5.2.2.3 In vivo polymer evaluation in xenograft HNSCC model 
JHU-022 human head and neck squamous cell carcinoma was first expanded from 
frozen stocks using RPMI 1640 medium supplemented with 10% FBS and 100mM L-
glutamine. Cells were harvested and suspended in cold phosphate buffered saline. Female 
athymic nu/nu 6 week old mice were injected with 2*10
6
 cells suspended in 200uL 
subcutaneously into the right flank under anesthesia using a 1mL syringe with a 26G 
needle. Cells were allowed to grow for approximately 10 days until tumor size was 
approximately equal to 5mm by 5mm to allow for intratumoral injection. Each SELP 
analog was thawed and diluted as above with adenovirus (Ad.Luc.HSVtk) and 0.9% 
NaCl injection saline to a final concentration of 5*10
8
 pfu and loaded into 0.5mL 
syringes with affixed 28G needles. On day 0, 25uL of each SELP analog with virus, virus 
alone, or PBS were injected into each tumor. On days 1 through 28, ganciclovir was 
injected intraperitoneally at a dose of 25mg/kg daily. Tumor size measurement was 
performed biweekly using calipers on the outside of each mouse with tumor volume 
computed by the formula length*width*width/2. Bioluminescent quantification was 
performed via injection of 200uL of luciferin at a concentration of 15mg/mL followed by 
imaging using a Xenogen IVIS 100 under anesthesia. Animals were monitored daily for 
weight, tumor size, and health. Any animal exhibiting signs of pain or distress, hunched 
posture, vocalization, isolation from the group, greater than 10% weight loss, greater than 
2000mm
3
 tumor burden, or ulceration of the skin at the tumor site were humanely 





or at day 50 for complete term animals and fixed in 10% neutral buffered formalin. 
Tissues were prepared, embedded, processed, and stained by ARUP laboratories. 
 
5.2.3 Analysis 
5.2.3.3 Statistical analysis 
Student’s t-test was used to compute statistical significance between two groups. One 
way ANOVA with a Tukey or Bartlett posttest was used to compute statistical analysis of 
groups of three or more. A value of p ≤ 0.05 was considered statistically significant and p 
≤ 0.01 was considered highly statistically significant. All error bars displayed represent 
standard deviation of the mean unless otherwise stated. 
 
5.3 Results 
5.3.1 Soluble polymer MMP digests 
Upon digestion of soluble forms of SELP815K and MMP-responsive SELPs with 
40nm MMP-2, SDS-PAGE analysis shows rapid digestion and breakdown of MMP-
responsive SELPs while SELP815K was resistant to degradation. Figure 5.1 shows a 
clear single band for all polymers at T=0 min, representing intact linear polymers. At 
T=10 min, SELP815K continues to show a clear single band while extensive laddering of 
the MMP-responsive SELPs was visible representing smaller molecular weight fragments 
of each polymer. At T=60 min, each responsive polymer was approaching complete 
digestion with most higher molecular weight bands no longer visible. The gel showing 
SELP815K continued to have a single band representing intact polymer strands through 






Figure 5.1: Digest of soluble (A) SELP815K, (B) SELP815K-RS1, (C) 
SELP815K-RS2, and (D) SELP815K-RS5 at a concentration of 1mg/mL with 
40nM MMP-2 at room temperature for 0, 10, 20, 30, 60, and 120 min 
visualized by SDS-PAGE in 20% acrylamide gels. Ladder in lane one on all 
gels is PAGEmark™ protein marker with visible bands representing from 
bottom 16kD, 20kD, 32kD, 48kD, 67kD, and 110kD. Full length polymer 






5.3.2 Hydrogel MMP digests 
Digestion of SELP hydrogels with 40nm MMP-2 resulted in quantifiable change to 
both the swelling ratios and soluble fraction released over 14 days. Across all polymers 
and concentrations, the swelling ratio increased after digestion with MMP-2 indicating an 
increase in the water content of each of the gels. Significance was achieved comparing 
digested and undigested SELP815K-RS2, 4 wt% (Figure 5.2A). Soluble fraction released 
by each of the polymers and gels increased by digestion with significance or high 
significance achieved in all except SELP815K-RS5 8 wt%. The lowest increase was 
observed in SELP815K-RS5 with less than a 20% increase observed at both 4 wt% and 8 
wt%. SELP815K showed an increase of up to 91% for both concentrations. The highest 
increases in degradation were observed in SELP815K-RS1 and SELP815K-RS2 with up 
to 185% increase in soluble polymer released from the hydrogels following digestion. 
Qualitatively, all MMP-responsive SELP hydrogels exhibited lower mechanical stability 
as demonstrated by difficulty in handling samples postdigestion. 
 
5.3.3 In vivo polymer evaluation 
Each polymer was tested as a matrix for localized viral mediated adenoviral gene 
delivery in head and neck tumor models. The SELP analogs were evaluated for their 
ability to mediate burst release of virus and elongate gene expression as assayed by 
bioluminescence, tumor size reduction, and increase in median survival. These 















Figure 5.2: Digest of 25uL hydrogels in 125uL of release media. SELP815K, 
SELP815K-RS1, SELP815K-RS2, and SELP815K-RS5 digested with 40nM MMP-2 
at room temperature for 14 days. White bars indicate undigested samples. Black bars 
indicated samples digested with MMP-2. Swelling ratio (A) defined as wet weight/dry 
weight. Soluble fraction (B) assayed by modified Lowry assay, above each polymer 
type and weight percent is the ratio of increase of soluble fraction due to digestion. 
815K:SELP815K, RS1:SELP815K-RS1, RS2:SELP815K-RS2, RS5:SELP815K-






5.3.3.1 In vivo efficacy in xenograft HNSCC model 
The gene expression observed as measure by bioluminescence in Figure 5.3A and 
displayed on logarithmic scale (inset) indicates all treatment groups maintain gene 
expression over 28 days 10 to 1000 fold over background bioluminescence indicating 
adequate expression during the treatment period. In the main body graph, burst 
expression is evident in the virus only, SELP815K, and SELP815K-RS1 4 wt% groups. 
Other treatment groups had lower burst release at the onset of the study with most groups 
normalizing to a more steady state release by day 14. No significance was obtained from 
bioluminescence data likely due to the variability of expression often observed with this 
biodistribution tracking technique. 
 The average tumor size increase of each group (Figure 5.3B) indicates tumor 
suppression was accomplished in all treatment groups. High statistical significance was 
achieved between all treatment groups and the PBS control. The treatment groups 
maintaining the lowest average tumor size were SELP815K 4t%, SELP815K-RS2 4%, 
SELP815K-RS1 8%, and SELP815K-RS2 8% although statistical significance was not 
achieved between individual treatment groups. Removal of animals due to health 
concerns or death prior to the end of study resulted in apparent growth stagnation in some 
groups such as the virus only and SELP815K-RS2 4%, as seen in Figure 5.4.  
Survival prolongation observed in the treatment groups are shown in Figure 5.4. 
Survival curves are divided between high and low weight percent test groups for clarity. 
SELP815K-RS1 8% and SELP815K-RS2 8% are the only groups to maintain 100% 
survival over the course of the 50 day study, and significance was achieved by the 

















Figure 5.3: In vivo evaluation of (A) viral gene expression elongation by 
bioluminescence generated by luciferase and (B) tumor size reduction by 
SELP815K, SELP815K-RS1, SELP815K-RS2, and SELP815K-RS5 matrix 
mediated local delivery. 815K:SELP815K, RS1:SELP815K-RS1, RS2:SELP815K-
RS2, RS5:SELP815K-RS5. ***- p≤0.001 between control (PBS) group and 
treatment groups by one way ANOVA with Bartlett posttest. (A) Data displayed on 










Figure 5.4: Survival elongation of SELP815K, SELP815K-RS1, SELP815K-RS2, and 
SELP815K-RS5 matrix mediated local delivery to solid tumor xenografts. (A) 4% wt/wt, 
5% RS5 and (B) 8% wt/wt. Groups split for clarity. 815K:SELP815K, RS1:SELP815K-
RS1, RS2:SELP815K-RS2, RS5:SELP815K-RS5. *- p≤0.05 achieved by Mantel-Cox 
test. Survival was defined as absence of death, pain or distress, greater than 10% weight 
loss, greater than 2000mm
3






maintained survival of approximately 86% throughout the study correlating to a single 
death in a seven mouse cohort. Virus only, PBS control, SELP815K-RS2 4% faired 
significantly worse with 29% to 43% survival. 
 
5.3.3.2 In vivo polymer degradation 
Histological examination of the polymer depots after 50 days of implantation reveals 
several key findings (Figure 5.5). In the SELP815K 4% group, limited cellular infiltration 
into the bulk material is observed; however, a clear border region is seen between the 
SELP and tumor tissue regions, defined by “S” for SELP and “T” for tumor on each 
histological panel, with little apparent erosion or invagination into the bulk material by 
neighboring tumor tissue. In contrast, the MMP-responsive SELPs at 4% show much 
higher cellular infiltration along with less clearly defined and more tortuous border region 
showing a mixture of biomaterial and tumor tissue. Neoplastic tissue appears to be 
advancing into the biomaterial in the MMP-responsive SELP groups. In the 8 wt% MMP-
responsive SELPs, the border regions are more clearly defined with lower cellular 
infiltration than 4% groups. However, there is still clearly tissue encroachment into the 
biomaterial as evidenced by advancing tumor tissue at the border of the hydrogel depots. 
Another more interesting finding is the presence of vascular remodeling into the 
biomaterial in all MMP-responsive SELPs except SELP815K-RS5, 5 wt% as indicated 
























Figure 5.5: Postnecropsy histological evaluation of SELP815K, SELP815K-RS1, 
SELP815K-RS2, and SELP815K-RS5 by hematoxylin and eosin staining after 50 days 
of implantation. White arrows indicate vascular infiltration of biomaterial. S:SELP 








An important attribute of polymers synthesized by recombinant techniques is the 
precise control over both the length and sequence of the resultant constructs. With such 
control, it is possible to systematically change the genetic code to affect polymer 
structure and properties resulting in a monodisperse product and thereby allowing direct 
comparison of the effects of each potential change. The MMP responsive SELPs 
investigated in this work displayed different outcomes in relative degree of degradation 
achieved through both in vitro and in vivo tests paired with observation of the ability of 
each polymer to act as a controlled release depot for matrix mediated gene therapy of 
solid tumors. These changes in physical properties demonstrated the structure to function 
relationship of each modification location.  
As expected, the MMP-responsive polymers used at a similar weight percent to non-
MMP-responsive polymers resulted in increased degradation, as evidenced by increased 
soluble polymer release in vitro as well as changes observed to the biomaterial after in 
vivo implantation. More unexpected, however, was the necessary increase in polymer 
concentration from SELP815K to MMP-responsive SELPs in order to impart similar 
results in a model of HNSCC. This increase in concentration was necessary to eliminate 
burst release and induce steady state release to match SELP815K 4%, which was 
ultimately demonstrated by survival elongation and tumor size suppression. Two factors 
are likely the cause of this variance. First is the perturbation of structure caused by the 
insertion of the MMP responsive site leading to changed mechanical properties observed 
previously,(19) and second, the perceived degradation of the MMP-responsive polymer 





The insertion of the responsive sequence was additionally expected to increase the pore 
size of each of the MMP-responsive SELPs as compared to the parent sequence 
SELP815K. In SELP815K-RS1 and SELP815K-RS2 with the responsive sequence in or 
adjacent to the elasin block, the eight amino acid insert should increase the length 
between silk blocks and as a consequence marginally increase the pore size of the 
respective hydrogels. The SELP815K-RS5 pore size was expected to increase further due 
to the structural disruption caused by interruption of the silk blocks also evidenced by the 
increase in soluble fraction and swelling ratio previously observed. It was unclear 
whether the increase in pore size would affect the degradation of the polymer hydrogels 
tested in this chapter. 
Initial degradability testing of the MMP-responsive SELPs, namely SELP815K-RS1, 
SELP815K-RS2, and SELP815K-RS5, consisting of incubation of soluble strands of each 
polymer with MMP-2, which is known to be overexpressed in a variety of cancers 
including HNSCC, showed rapid degradation of each MMP-responsive polymer. In 
contrast, SELP815K without MMP-responsive functionality showed little degradation 
over the course of the 120 min experiment. As seen in Figure 5.1B, 5.1C, and 5.1D, each 
of the MMP-responsive SELPs appeared to degrade on a similar timescale indicating the 
site of MMP-responsive sequence insertion in the polymer backbone did not affect 
cleavage rate when polymers are in the soluble, and therefore linear form. This 
observation did not fully extend to degradation of the hydrogel form of each SELP 
construct.   
Degradation of hydrogel forms of each of the SELPs showed a trend of increased 





Figure 5.2A. Soluble polymer release during degradation of the gels revealed a 
statistically significant increase in polymer content lost from each hydrogel in all 
polymers tested except SELP815K-RS5. The increase in release of soluble fraction 
observed from SELP815K is likely due to the ability of MMP-2 to function as a broad 
spectrum gelatinase with a long study time scale of 14 continuous days. The increase in 
polymer release from SELP815K-RS1 and SELP815K-RS2 gels was much higher, with 
up to a 185% increase as compared to SELP815K, which released a maximum of 91% 
increase after digestion. These results show increased digestion in MMP-responsive 
SELPs. However, these high release fractions were not observed in SELP815K-RS5. A 
likely explanation is the location of the responsive site. In SELP815K-RS5, the 
responsive site resides within the silk block of the SELP monomer, which is the main 
structural unit of the polymer primarily forming beta sheets. This structural formation 
may physically impede access of MMP-2 to the responsive site, unlike in SELP815K-
RS1 and SELP815K-RS2 where inserts reside at the junction of the silk and elastin 
blocks and within the elastin block, respectively. This degradation of SELPs by MMPs in 
hydrogels may be site specific, which was not evident when digesting soluble polymers. 
The hypothesis of steric inhibition of enzyme access correlates to previous work showing 
significant structural disruption in SELP815K-RS5, with responsive site inserted into the 
silk units, evidenced by an increased swelling ratio, soluble fraction release, and 
minimum gel forming concentration.(19) This leads to the deduction that structurally 
important regions of the polymer backbone may be inaccessible in the hydrogel state. 
Importantly, further analysis on the soluble fraction is warranted to yield more 





degradation could point to the cleavage of structural regions of the hydrogel releasing 
trapped soluble polymer while a higher degree of fragmented strands could indicate more 
extensive cleavage of the hydrogel structure itself, thus liberating gel fragments. 
 In addition to measuring soluble fraction, qualitative observation of gel physical 
characteristics occurring during sample transfer postdegradation revealed decreased 
mechanical stability in MMP-responsive hydrogel samples. As polymer strands are cut, 
the long-range interactions throughout the gels are reduced affecting the robustness of 
each gel and leading to more difficulty in maintaining physical integrity during sample 
manipulation. This finding also supports the supposition of degradation within each 
hydrogel. The loss of mechanical properties combined with the observation of no change 
in size despite over 40% protein loss in some hydrogel samples leads to the conclusion of 
MMP-2 penetration into the hydrogels and as a consequence bulk degradation instead of 
surface degradation. Further analyses to prove this phenomenon may include polarized 
light microscopy to examine long-range structure within the hydrogels before and after 
digestion or small angle neutron scattering which may show an increase in pore size 
following degradation with MMP-2.(24, 25) 
The in vivo evaluation of MMP-responsive SELPs in comparison with the previous 
most effective treatment, SELP815K 4% (Figure 2.3,(26)), within the scope of matrix 
mediated viral gene therapy was the most important test of applicability of each polymer 
modification. Bioluminescence data used as semiquantitative expression testing of the 
viral constructs through the luciferase reporter gene indicated a decrease of initial burst 
expression by 8% MMP-responsive SELPs that is commonly seen in virus only injection 





in raising the concentration of SELPs and has been noted previously in other SELP 
constructs.(10) This figure also shows maintenance of bioluminescence expression 
greater than 10 fold higher than background for all groups through day 28 indicating 
long-term release of virus from all SELP hydrogels. The reduction in burst release also 
proved to be an indicator of performance in tumor size suppression. 
Tumor suppression also monitored in this study and displayed in Figure 5.4B showed 
statistical significance between all treatment groups when compared to the PBS injected 
control, indicating effective knock down of tumor size by viral mediated gene therapy. 
Significance was not achieved between individual treatment groups. The most effective 
polymers at suppressing tumor growth were shown to be SELP815K 4%, SELP815K-
RS2 4%, SELP815K-RS1 8%, and SELP815K-RS2 8%. Statistically equivalent 
treatment between these groups was observed, but SELP815K 4% and SELP815K-RS2 
4% lost cohort members to death prior to the end of the study, by resulting in an 
artificially suppressed reported tumor size. Tumor size data should be evaluated within 
the context of overall survival, as shown in Figure 5.5, to indicate true effectiveness of 
treatment. Of all groups tested, SELP815K-RS1 8%, and SELP815K-RS2 8% were the 
only two treatments to achieve 100% survival over the 50 day study with significance 
achieved by the Mantel-Cox test. Furthermore, these results may indicate 8% wt/wt 
polymers are required for MMP-responsive SELPs to account for release rate increase 
caused by degradation, as previous reports have shown SELP815K at a concentration of 
8% to be less effective in the treatment of solid tumors by matrix mediated gene 
therapy.(27) 





were excised and examined by hematoxylin and eosin staining to show tissue interaction. 
Typically, hallmark signs of gel degradation in a nontumor environment include the 
presence of active inflammatory cells at the implant border including macrophages, 
monocytes, and lymphocytes, whereas a nondegradable implant would likely be 
surrounded by less active cells such as fibroblasts by the end of the study at day 50. This 
study, however, takes place within a tumor microenvironment which is known to be 
highly immune suppressed.(28) As a result, the primary signs of gel degradation are from 
the tumor tissue itself invading through the production of MMPs and other proteases. As 
observed previously,(17) SELP815K 4% showed little evidence of degradation in vivo as 
demonstrated by a clear border region between tumor tissue and gel implant with fibrosis 
identified in multiple samples. Limited cellular infiltration of the gel mass was also 
observed. To the contrary, all MMP-responsive SELPs at 4% or 5% showed increased 
cellular infiltration as well as apparent encroachment of neoplastic tissue into the 
biomaterial as visualized by a marbled appearance of border regions containing both 
tissue and biomaterial. Tissue penetration into the biomaterial was not observed in any of 
the SELP815K samples suggesting the MMP-responsive modification to the SELP 
polymer backbone allowed for degradation by the invading tumor tissue through 
production of MMPs. This further supports the hypothesis of higher weight percent 
MMP-responsive hydrogels being necessary for an effective treatment of solid tumors 
due to increased release rate triggered by degradation. Additional staining with Masson’s 
trichrome in the future will be key to identify fibrotic regions of the injection site and to 
confirm the absence of encapsulation around MMP-responsive hydrogels. 





to develop mature T-cells. As a result, xenograft tumor establishment is possible, but T-
cell mediated immune response is absent while other immune responses are diminished 
due to the interplay between T-cells and other immune cells to mount an effective 
immune response. This leads to several caveats to the findings in this work. Firstly, with 
an intact immune system the viruses at the tumor site may be cleared more quickly 
leading to diminished treatment effectiveness. The opposite may also be true in that the 
resultant inflammation at the injection site could negatively impact tumor survival. 
Similarly, the degradation or encapsulation responses observed in these studies may be 
enhanced by the presence of mature T-cells. To evaluate the impact of the immune 
system on the observed results, the in vivo model should be repeated in a CD-1 
immunocompetent mouse model with the S-180 sarcoma tumor cell line.  
Vascular remodeling was also identified in many of the MMP-responsive hydrogel 
samples as evidenced by the appearance of vessels carrying red blood cells within the gel 
mass. Neovasculature normally found in granulation tissue would have likely resolved by 
the end of the study at day 50 and be absent in histological sections. This indicates the 
vasculature may be tumor associated, and be driven by the production of MMPs. These 
findings further the conclusion that the in vivo degradation is occurring in MMP-
responsive SELPs due to interaction with host tissues. Additionally, these results 
represent a potential for the use of MMP responsive SELPs as a biomaterial in 
applications that require remodeling of the material such as wound healing as evidenced 
by vascular penetration into the gel mass. 







SELP815K along with three MMP-responsive analogs, namely SELP815K-RS1, 
SELP815K-RS2, and SELP815K-RS5 were evaluated for degradation in vitro in the 
presence of MMP-2 and in vivo in the presence of head and neck cancer solid tumors. All 
MMP-responsive SELPs showed increased degradation in the presence of MMP-2 in 
both soluble and hydrogel forms. SELP815K-RS1 and SELP815K-RS2 showed 
significantly higher degradation compared to SELP815K while the likely steric hindrance 
of the silk block insertion site of SELP815-RS5 in hydrogel form limited the impact of 
MMP-2 digestion. SELP815K-RS1 and SELP815K-RS2 at 8% wt/wt showed the most 
effective cancer treatment as a matrix to mediate viral gene therapy by increasing 
survival from 29% to 100% over 50 days compared to the control group and maintaining 
lower tumor sizes. Further, histological examination of polymer depots following 
implantation revealed evidence of degradation in MMP-responsive SELPs not seen in 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
The results of this body of work show the power of recombinant polymers as tunable 
systems that can be tailored through site specific insertions of amino acid sequences. The 
exquisite control over sequence afforded by recombinant DNA technology allows for 
structure to function relationships to be elucidated by systematic alteration of the base 
sequence of protein based polymers. This allows us to easily add or remove functionality 
to the recombinant polymer system. 
SELP815K, despite exceeding as a controlled release depot, and showing increased 
efficacy and decreased toxicity when compared to free viral injection or other polymers 
commonly used in MMGD, does not freely degrade to be resorbed into the body. In 
Chapter 3 the application of SELP815K was the only treatment compared to poloxamer 
and virus only to achieve 100% survival over the 50 day efficacy study. Further, 
SELP815K showed more prolonged bioluminescence expression compared to the other 
treatment groups representing prolonged controlled release of the adenoviral payload. 
Mediation of adenoviral toxicity as manifested in lower white blood cell counts at earlier 





SELP815K mediated therapy. Despite these benefits, in a 12 week residence study the 
SELP815K polymer depot was not resorbed, but rather encapsulated. In order to 
overcome this challenge in subsequent chapters new biodegradable polymers were 
designed and evaluated. 
It was hypothesized that by inserting MMP responsive motifs into the polymer 
backbone, it would be possible to increase the degradation rate of the polymers in the 
presence of MMPs, which are commonly overexpressed in the disease target. Insertions 
were made in two additional sites in the SELP815K polymer backbone yielding three 
total constructs, namely within the silk block termed SELP815K-RS5, within the elastin 
block termed SELP815K-RS2, and at the junction between these two structural motifs 
termed SELP815K-RS1. Examination of the physiochemical properties of the resulting 
polymers demonstrated disruption of mechanical properties, dependent on proximity to 
the silk blocks, and particularly in SELP815K-RS5 rendering it useless for controlled 
release applications primarily due to increase of the minimum gel forming concentration 
to 13% wt/wt. Through the careful design of a physical conditioning step utilizing high 
shear force the mechanical properties were rescued and showed the new polymers to be 
suitable for application in MMGD. 
In Chapter 5 it was shown that the constructs SELP815K-RS1 and SELP815K-RS2 
with insertions at the junction of silk and elastin blocks, and within the elastin blocks, 
respectively, had increased degradation in soluble form as well as in hydrogel form 
compared to SELP815K. Their application to a xenograft model of head and neck cancer 
results in increased survival of treatment animals compared to SELP815K, SELP815K-





Further, mediation of burst release of virus typically seen in virus only injection and 
SELP815K 4% was recorded in the 8% MMP-responsive SELP groups. This result is 
linked back to Chapter 4 which showed relatively little perturbation of the 
physiochemical properties incurred by the insertion of the MMP-responsive sequence 
within the elastin units and at the junction of silk and elastin. By not severely altering the 
structure in these two analogs, slower initial release from the gels observed previously in 
SELP815K 8% was realized. Finally, histological examination showed degradation 
occurring at the border between tumor tissue and the MMP-responsive SELPs. The less 
favorable in vitro results including decreased evidence of digestion of SELP815K-RS5 in 
hydrogel form can be linked back to the insert location within the primary structural 
component of SELP polymers, as seen in Chapter 4. The result of the use of SELP815K-
RS1 and SELP815K-RS2 prove the initial hypothesis drawn from the challenge presented 
in Chapter 3. 
 
6.2 Challenges and future directions 
The next logical steps in this project require several follow on experiments for the 
clarification of obtained results. First, the quantitative biodistribution of virus released 
from MMP-responsive hydrogels via quantitative PCR is warranted to ensure restriction 
of the virus to tumor tissues. Further, the staining of tumor tissue by 
immunohistochemistry for viral capsid proteins will allow for a visual characterization of 
penetration and viral expression throughout the study time points. Additionally, the data 
presented in this dissertation use a model GDEPT system composed of 





addition of several features. First, the combination of ganciclovir/thymidine kinase with 
5-fluorocytosine/cytosine deaminase GDEPT system would allow for greater tumor 
suppression due to the established synergistic interaction between these treatments.(1) 
Secondly, the single injection strategy used in these studies in order to more clearly 
observe the differences between treatment systems should be replaced with a multiple 
injection strategy allowing for more complete penetration of the tumor tissue. Thirdly, the 
use of the lysine motifs for conjugation of chemotherapeutics such as cisplatin should be 
completed to allow for further local combination therapy and better treatment 
outcomes.(2) 
Moving forward with MMP-responsive SELPs entails several challenges that must be 
met before translation to the human disease condition can be accomplished. First, 
quantitative long-term analysis of the interaction of these polymers with the immune 
system must be carried out. This work would entail not only experimentally proving the 
absence of immune response in single dose trials, but also repeat dose experiments 
necessary to allow repeat administration of the polymer depots if needed.(3) Secondly, 
complete mapping of degradation products will be necessary to prove no toxic 
degradation products are formed in the digestion of both linear polymers and hydrogels. 
This may be accomplished through analysis of the MMP-2 digested linear polymers and 
hydrogel soluble fraction by SDS-PAGE gels as well as mass spectroscopy. Further, 
digested samples should be tested for inhibition of proliferation in cell cultures studies as 
well as assayed for toxic response when injected into in vivo models. The third important 
avenue to pursue is the comparison of MMP-responsive SELP mediated GDEPT with 





chemotherapy. Without concrete data proving benefit of this system over the current state 
of the art, there will be no driving force to bring this technology past the small animal 
testing phase. The necessity of these experiments is compounded by the use of a novel 
biomaterial that has not yet been approved for use in humans in any indication together 
with viral gene carriers that have a storied past (being linked to deaths in nonterminally 
ill patients in clinical trials).(4, 5) Though these incidents have since been proven the 
fault of extraneous circumstances and investigator error, the viral stigma remains.(5, 6) 
Further study of the mechanism of shearing is also warranted. Though the shearing 
process is reproducible and normalizes the properties of SELP polymers, the actual 
effects on secondary and tertiary structure have yet to be determined. Examination of the 
polymers before and after shearing through circular dichroism or polarized light 
microscopy may lead to a better understanding of this phenomenon. 
This work also presents the opportunity to apply the SELP polymer system to other 
indications in which the system may be tailored to any local delivery requirements based 
on the specific environmental cues for each disease state. One such potential use is local 
therapy in neuro-oncology applications. There is much room for improvement compared 
to the state-of-the-art embodied by current nonstimuli-responsive systems, which afford 
patients a survival increase of less than 3 months compared to surgery alone.(7) 
Localized therapy of nonresectable pancreatic cancers also presents a promising 
opportunity to impact patient outcomes through the use of drugs that have dose limiting 
toxicity when applied systemically.(8) Lastly, the application of these SELP polymers to 
chronic inflammatory diseases represents an application in that environmental 





enzymes typical of inflammatory tissue destruction would allow for treatment tailored to 
the degree of inflammation present and flare ups in the disease state. 
More broadly controlled release in a biological environment typically entails long-
term residence of the delivery system. Long-term biocompatibility of SELPs remains an 
area requiring further exploration and would be application specific. Establishment of 
quantitative immunogenicity is becoming more imperative as additional degradable 
systems are designed for controlled release. For degradable systems, fine tuning the rate 
of degradation remains a challenge that may be accomplished through quantitation of 
degradation rates followed by blending of polymer constructs for fine tuning. Designing 
stimuli sensitive polymers requires detailed understanding of the environment where the 
recombinant polymer system will reside. In a diseased environment, a tumor, for 
example, the local enzymes will be different or expressed at altered concentrations as 
compared to normal milieu. Biorecognizable motifs incorporated into the recombinant 
polymer identified by local enzymes in the diseased milieu may provide an effective 
strategy for rate control. However, structure and function of the polymer may be 
compromised. Furthermore, the tertiary structure of the designed recombinant polymer 
and targeting local enzyme must be well characterized to determine compatibility for 
interaction and desired outcome. Finally, high production costs remain a challenge in this 
field, particularly scaling up production and purification of recombinant polymers for 
commercial use.  
Despite these challenges the true usefulness of recombinant DNA technology is only 
starting to be realized with the rise of inexpensive computing power which may lead to 





modeling recombinant proteins after sequences derived from nature has been widely 
shown to be a formula for successful assignment of functionality. As this modeling 
becomes more powerful and available the production of designer proteins with specific 
engineered functions from novel amino acid sequences will become possible. In addition, 
development of combinatorial approaches for the synthesis of a myriad of polymer 
structures at the same time and their subsequent high throughput evaluation can 
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Figure A.3: Mass spectrum of SELP815K-RS5 polymer by matrix-assisted laser 
desorption ionization. 
 
 
